WO2008012343A2 - Macrolide synthesis process - Google Patents

Macrolide synthesis process Download PDF

Info

Publication number
WO2008012343A2
WO2008012343A2 PCT/EP2007/057710 EP2007057710W WO2008012343A2 WO 2008012343 A2 WO2008012343 A2 WO 2008012343A2 EP 2007057710 W EP2007057710 W EP 2007057710W WO 2008012343 A2 WO2008012343 A2 WO 2008012343A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
piperidinyl
tylosin
formula
hydrogen
Prior art date
Application number
PCT/EP2007/057710
Other languages
French (fr)
Other versions
WO2008012343A3 (en
Inventor
Fritz Blatter
Meinrad Brenner
Monika Brink
Kerstin Fleischhauer
Guixian Hu
Hans Peter Niedermann
Timo Rager
Tanja Schweisel
Stephan Veit
Ralf Warrass
Heinz-Jörg WENNESHEIMER
Original Assignee
Intervet International B.V.
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200730813T priority Critical patent/SI2089408T1/en
Priority to ES07787934T priority patent/ES2374950T3/en
Priority to CA2657483A priority patent/CA2657483C/en
Priority to KR1020097003914A priority patent/KR101456308B1/en
Priority to MX2009001072A priority patent/MX2009001072A/en
Priority to BRPI0715642A priority patent/BRPI0715642C8/en
Priority to EP07787934A priority patent/EP2089408B1/en
Application filed by Intervet International B.V., Microbial Chemistry Research Foundation filed Critical Intervet International B.V.
Priority to AT07787934T priority patent/ATE528312T1/en
Priority to CN200780031395XA priority patent/CN101506220B/en
Priority to PL07787934T priority patent/PL2089408T3/en
Priority to NZ574193A priority patent/NZ574193A/en
Priority to JP2009521274A priority patent/JP5323696B2/en
Priority to KR1020147011035A priority patent/KR101538599B1/en
Priority to AU2007278195A priority patent/AU2007278195B2/en
Priority to UAA200901136A priority patent/UA98303C2/en
Publication of WO2008012343A2 publication Critical patent/WO2008012343A2/en
Publication of WO2008012343A3 publication Critical patent/WO2008012343A3/en
Priority to ZA2009/00387A priority patent/ZA200900387B/en
Priority to HK10100071.0A priority patent/HK1132510A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide and derivatives thereof, as well as methods of treatment using such macrolides, uses of such macrolides to make medicaments, and methods for making intermediates that, inter alia, may be used to make macrolides.
  • Macrolides have long been known to be effective for treating infectious diseases in humans, livestock, poultry, and other animals. Early macrolides included 16- membered macrolides such as, for example, tylosin A:
  • Tylosin derivatives include, for example, compounds discussed in U.S. Patent No. 6,514,946 that correspond in structure to Formula (I):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; R 1 and R 3 are each hydrogen, and R 2 is methyl; or R 1 , R 2 , and R 3 are each hydrogen; and
  • R 4 and R 6 are each methyl, and R 5 is hydrogen; R 4 and R 6 are each hydrogen, and R 5 is methyl; or R 4 , R 5 , and R 6 are each hydrogen.
  • Such compounds include, for example, 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, which has the following structure:
  • R, R 1 , R 2 , R 3 , and R 4 are defined as various substituents.
  • R, in particular, is defined as a nitrogen-containing ring system that has up to 3 unsaturated or saturated rings that are optionally substituted.
  • Debono et al. report that the preferred reducing agent is a cyanoborohydride, and that sodium cyanoborohydride is "the reducing agent of choice.”
  • Debono et al. also state that the solvent for this reaction will normally be an inert polar solvent, such as a Ci -C 4 alkanol. See page 6, lines 7-14. In a later-filed patent in the same patent family, Debono et al.
  • R p 2 , R4, R7 and R8 are defined as various substituents.
  • R7 and R8, in particular, are each defined as being independent substituents, or, alternatively, as together forming a 3- to 7-member heterocyclic ring.
  • Phan et al. discuss conducting this reaction with a boro hydride reagent in an alcohol or acetonitrile solvent.
  • Sodium borohydride and sodium cyanoborohydride are listed as example borohydride reagents; and methanol, ethanol, and isopropanol are listed as example alcohol solvents. See, e.g., col. 15, line 64 to col. 16, line 42; and col. 22, lines 41-49.
  • R 1 , R 2 , R 3 , and R 4 are defined as various substituents.
  • R 3 and R 4 are defined as each being independent substituents, or, alternatively, as together forming a heterocyclic ring system having up to 3 optionally substituted rings.
  • Tao et al. report that this reduction may be achieved using formic acid as the reducing agent.
  • Tao et al. further report that the solvent will ordinarily be an inert polar organic solvent. Amyl acetate and acetonitrile are cited as examples of such a solvent. See page 4, line 57 to page 5, line 10. See also, U.S. Patent No. 4,921,947, col. 3, line 62 to col. 4, line 16.
  • R, R 1 , R 2 , and R 4 are defined as various substituents.
  • Debono et al. report that this "hydrolysis can be effected using a strong aqueous mineral acid as hydrochloric or sulfuric acid, or a strong organic acid such as/?-toluenesulfonic acid.” See page 7, lines 3-8.
  • Debono et al. further discuss mycarose
  • This invention relates to processes for making macrolides, and, in particular, optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof.
  • Such processes include processes for making the macrolides themselves, as well as processes for making compounds that, inter alia, may be used as intermediates for making various macrolides.
  • this invention is directed, in part, to a process for making a macro lide and salts thereof.
  • the macro lide corresponds in structure to Formula (I):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen
  • R 1 and R 3 are each hydrogen, and R 2 is methyl, or
  • R 1 , R 2 , and R 3 are each hydrogen.
  • R 4 , R 5 , and R 6 are each hydrogen.
  • R 4 and R 6 are each methyl, and R 5 is hydrogen
  • R 4 and R 6 are each hydrogen, and R 5 is methyl, or
  • R 4 , R 5 , and R 6 are each hydrogen.
  • the process comprises reacting tylosin (e.g., tylosin A or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent.
  • tylosin e.g., tylosin A or a salt thereof
  • piperidinyl compound of Formula (II) corresponds in structure to:
  • the process comprises reacting a 20-piperidinyl- tylosin compound with an acid.
  • the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III):
  • the process comprises reacting a 23-O-mycinosyl- 20-piperidinyl-5-O-mycaminosyl-tylonolide compound with an acid.
  • the 23 -0-mycino syl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound corresponds in structure to Formula (IV):
  • the process comprises activating a 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound with an activating agent to form an activated compound.
  • the 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound corresponds in structure to Formula (V):
  • the activated compound (also referred to as a "23-L-20-piperidinyl-5-O-mycaminosyl- tylonolide compound”) corresponds in structure to Formula (VI):
  • the process comprises reacting an activated compound of Formula (VI) with a piperidinyl compound of Formula (VII).
  • the piperidinyl compound of Formula (VII) corresponds in structure to:
  • the process comprises a combination of the above embodiments to make a macro lide of Formula (I) or salt thereof.
  • the process comprises one or more of the above embodiments to make, for example, an amorphous, crystalline, co-crystalline, or solvate form of the macrolide of Formula (I) or a salt thereof.
  • This invention also is directed, in part, to a process for making the 20- piperidinyl-tylosin compound of Formula (III) or a salt thereof.
  • the process comprises reacting tylosin (e.g., tylosin A), the piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent.
  • This invention also is directed, in part, to a process for making the 23-0- mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (IV) or a salt thereof.
  • the process comprises reacting the 20-piperidinyl- tylosin compound of Formula (III) with HBr.
  • This invention also is directed, in part, to a process for making a 23- hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (V) or a salt thereof.
  • the process comprises reacting the 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (IV) with an acid.
  • This invention also is directed, in part, to a process for making an activated compound of Formula (VI) or a salt thereof.
  • the process comprises activating a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (V) with an activating agent.
  • This invention also relates to using compounds of Formula (I) (and pharmaceutically acceptable salts thereof) prepared in accordance with this invention in methods for treating a disease, such as pasteurellosis, swine respiratory disease, or bovine respiratory disease. More specifically, this invention is directed, in part, to a method that comprises preparing a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) in accordance with one or more of the above cited methods, and then administering a therapeutically effective amount of the compound or salt to an animal in need of the treatment. This invention also is directed, in part, to using a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) prepared in accordance with this invention to prepare a medicament, particularly a medicament for use in the above treatments.
  • a disease such as pasteurellosis, swine respiratory disease, or bovine respiratory disease. More specifically, this invention is directed, in part, to a method that comprises preparing a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) in accordance with one
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; R 1 and R 3 are each hydrogen, and R 2 is methyl; or R 1 , R 2 , and R 3 are each hydrogen; and
  • R 4 and R 6 are each methyl, and R 5 is hydrogen; R 4 and R 6 are each hydrogen, and R 5 is methyl; or R 4 , R 5 , and R 6 are each hydrogen.
  • the piperidinyl substituents of Formula (I) are identical, i.e.
  • both piperidinyl substituents are piperidine (i.e., RR 11 ,, RR 22 ,, RR 33 ,, RR 44 ,, RR 55 ,, aanndd RR 66 aarree eeaacchh hhyyddrrooggeenn), such that the compound is 20,23- dipiperidinyl-5 -0-mycamino syl-tylono lide :
  • Such compounds include, for example:
  • piperidinyl substituents of Formula (I) are not identical, i.e. :
  • This invention may be used to synthesize macro lides from materials generally available in the art.
  • the macrolide synthesis begins by or includes preparing a 20-piperidinyl-tylosin compound, and particularly a compound corresponding in structure to Formula (III):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; or R 1 and R 3 are each hydrogen, and R 2 is methyl. In other embodiments, R 1 , R 2 , and R 3 are each hydrogen, such that the compound corresponds in structure to:
  • the 20-piperidinyl-tylosin compound may be prepared from tylosin A and a piperidinyl compound via a reductive amination reaction using a reducing agent comprising formic acid (or "HCOOH”):
  • Tylosin A piperidinyl compounds, and formic acid are commercially available.
  • the tylosin A reagent may, for example, be pure (or at least essentially pure) tylosin A.
  • the tylosin A reagent may be part of a mixture, such as, for example, a mixture comprising tylosin A as well as one or more tylosin A derivatives, such as tylosin B, tylosin C, and/or tylosin D.
  • the tylosin A may be in the form of its free base, or, alternatively, in the form of a salt.
  • the tylosin A derivatives likewise are optionally in the form of one or more salts. It is contemplated that a variety of salts may be suitable.
  • the salt comprises a phosphate salt.
  • the salt comprises a tartrate salt.
  • the salt comprises a citrate or sulfate salt. Further discussion relating to salts may be found below in Section C.
  • the solvent may comprise one or more solvents. Although the solvent may comprise one or more polar solvents in some embodiments, the solvent preferably instead comprises one or more non-polar solvents.
  • a "non-polar solvent” is a solvent that does not ionize sufficiently to be electrically conductive, and cannot (or at least essentially cannot) dissolve polar compounds (e.g., various inorganic salts), but can dissolve nonpolar compounds (e.g., hydrocarbons and resins).
  • the solvent preferably is non- reactive with the reagents, products, and any other ingredients in the reaction mixture.
  • the solvent may comprise, for example, chloroform (or "CHCI 3 "); tetrahydrofuran (or “THF”); dichloromethane (or “CH 2 Cl 2 “ or “DCM” or “methylene chloride”); carbon tetrachloride (or “CCl 4 "); ethyl acetate (or “CH 3 COOC 2 H 5 “); diethyl ether (or “CH 3 CH 2 OCH 2 CH 3 "); cyclohexane (or “C 6 Hi 2 "); or aromatic hydrocarbon solvents, such as benzene (or “C 6 H 6 “), toluene (or “C 6 H 5 CH 3 "), xylene (or “C 6 H 4 (CHs) 2 " or “dimethylbenzene” (including 1,3- dimethylbenzene (or “m-xylene”), 1 ,2-dimethylbenzene (or “o-xylene”), or 1,4- dimethylbenzene (or “/ ⁇ -xylene
  • the solvent comprises dichloromethane, chloroform, or ethyl acetate. In other embodiments, the solvent comprises xylene. In still other embodiments, the solvent comprises toluene. In some such embodiments, toluene is particularly preferred because of its ease of use at typical reaction temperatures. [35] In some embodiments, the solvent comprises a mixture of solvents. In some such embodiments, for example, the solvent comprises a mixture of toluene and DCM.
  • the toluene/DCM ratio may be, for example, from about 1 :1 to about 100:1, or from about 5:1 to about 8:1 (v/v). In some of these embodiments, the ratio is, for example, about 8:1 (v/v).
  • the ratio is, for example, about 5.3:1 (v/v).
  • the tylosin A reagent, piperidinyl compound, formic acid (or a source of formic acid), and solvent normally are charged to a reactor and mixed. These ingredients may generally be charged to the reactor in any sequence.
  • the reactor may comprise various reactor types.
  • the reactor is a stirred-tank reactor.
  • Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the reaction mixture may be used.
  • stainless steel reactors generally may be used as well.
  • tylosin A reagent typically, equimolar amounts of the tylosin A reagent, piperidinyl compound, and formic acid may be used. Normally, however, excess amounts of the piperidinyl compound and formic acid are used, relative to the molar amount of tylosin A reagent.
  • from 1 to about 3 equivalents (or from 1.05 to about 3 equivalents) of the piperidinyl compound are charged to the reactor.
  • from 1.05 to about 1.2 equivalents of piperidinyl compound are charged to the reactor.
  • from about 1.07 to about 1.5 equivalents of piperidinyl compound are charged to the reactor.
  • about 1.3 equivalents of the piperidinyl compound may be charged to the reactor.
  • the piperidinyl compound is charged to the reactor in two or more separate charges over time, preferably with the subsequent charge(s) being less than the first charge.
  • the piperidinyl compound is charged to the reactor in two charges, with the amount of the second charge being about 10% of the first charge. Applicants have discovered that this can be beneficial for increasing conversion.
  • from 1 to about 10 equivalents (or from 1.05 to about 10 equivalents, from about 2 to about 5 equivalents, or from about 2.5 to about 4.5 equivalents) of formic acid are used.
  • about 4.5 equivalents of formic acid are used.
  • from about 2.5 to about 4 equivalents of formic acid are used.
  • about 3.0 equivalents of formic acid are used.
  • the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents.
  • the amount of solvent is at least about 1 L per kg tylosin A reagent (or, where the tylosin A reagent is part of a mixture of tylosin A reagent and derivates thereof, per kg of the total tylosin mixture).
  • the amount of solvent generally is less than about 40 L per kg tylosin A reagent (or tylosin mixture).
  • the amount of solvent is from about 2 to about 15 L (or from about 5 to about 15 L, from about 5 to about 12 L, from about 5 to about 10 L, or from about 8 to about 10 L) per kg tylosin A reagent (or tylosin mixture).
  • the solvent comprises toluene or a mixture of toluene and DCM, and the amount of solvent is from about 8 to about 10 L per kg tylosin A reagent (or tylosin mixture).
  • the amount of solvent may be about 8 L per kg tylosin A reagent (or tylosin mixture).
  • At least a portion of the reaction (or the entire reaction) is typically conducted at greater than about 2O 0 C, greater than about 25 0 C, or greater than about 6O 0 C. In general, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and, more typically, is less than the boiling point.
  • the solvent is toluene
  • at least a portion of the reaction (or the entire reaction) is typically conducted at less than about HO 0 C.
  • the solvent is xylene
  • at least a portion of the reaction (or the entire reaction) is normally conducted at less than about 165 0 C.
  • At least a portion of the reaction is conducted at from about 60 to about 95 0 C, from about 70 to about 85 0 C, from about 70 to about 8O 0 C, or from about 75 to about 8O 0 C.
  • the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 8O 0 C.
  • the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 76 0 C.
  • This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure. In preferred embodiments, this reaction is conducted under an inert atmosphere (e.g., N 2 ).
  • an inert atmosphere e.g., N 2
  • the reaction time may depend on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion.
  • the reaction time is generally at least about 1 minute, typically at least about 5 minutes, and more typically at least about 1 hour.
  • the reaction time is generally less than about 24 hours.
  • the reaction time is from about 0.5 to about 12 hours, or from about 1 to about 4 hours.
  • the reaction time is about 3.5 hours.
  • the reaction time is from about 1 to about 3 hours.
  • the reaction time may be, for example, about 2 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
  • Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
  • the macrolide synthesis begins by or includes preparing a 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure to Formula (IV):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; or R 1 and R 3 are each hydrogen, and R 2 is methyl. In other embodiments, R 1 , R 2 , and R 3 are each hydrogen such that the compound corresponds in structure to:
  • the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound may be prepared via acid hydrolysis of a 20-piperidinyl-tylosin compound:
  • the 20-piperidinyl-tylosin compound used in the above reaction may be prepared using a process discussed above in Section B-I, prepared using a different process (e.g. , a process using a borohydride as a reducing agent), or obtained from a commercial vendor.
  • the 20-piperidinyl-tylosin compound is prepared using a process discussed above in Section B-I.
  • the acid may, for example, be a strong mineral acid, such as hydrochloric acid (or “HCl”), nitric acid (or “HNO 3 “), fluoroboric acid (or “HBF 4 "), sulfuric acid (or “H 2 SO 4 "), phosphoric acid (or “H 3 PO 4 "), polyphosphonic acid (or “PPA”), or hydrobromic acid (or “HBr”); or a strong organic acid, such as/?-toluenesulfonic acid or trifluoroacetic acid (“CF 3 COOH”).
  • the acid comprises HCl.
  • the acid comprises HBr. Use of HBr tends to coincide with a less amount of impurities in the product mixture relative to the product obtained using, for example, HCl.
  • a mixture of acids is used.
  • sufficient acid is mixed with the 20-piperidinyl-tylosin compound to hydro lyze (i.e., cleave) the mycarosyloxy substituent to form a hydroxyl group.
  • the amount of acid will be at least about one equivalent, based on the amount of 20-piperidinyl-tylosin compound.
  • the acid is added to the reaction mixture in the form of a concentrated composition. The concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30% (mass/vol), or from about 1 to about 24% (mass/vol).
  • the acid is HBr
  • the concentration of the acid solution added to the reaction mixture is about 24% (mass/vol).
  • the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.
  • the ingredients may generally be charged to the reactor in any sequence.
  • the reactor may comprise various reactor types.
  • the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the acidic reaction mixture may be used.
  • At least a portion of the hydrolysis normally is conducted at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous.
  • a temperature of at least about 1O 0 C (or greater than about 15 0 C, or greater than about 25 0 C) is typically preferred.
  • the reaction temperature is not greater than the boiling point of the solvent (e.g., water), and typically is less than the boiling point.
  • at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 100 0 C (or not greater than about 65 0 C).
  • the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 20 to about 6O 0 C. In some such embodiments, the reaction temperature over at least a portion of the reaction (or the entire reaction) is not greater than about 4O 0 C. In such instances, the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, from about 20 to about 4O 0 C, from about 25 to about 4O 0 C, or from about 30 to about 4O 0 C.
  • the reaction temperature over at least a portion of the reaction is from about 45 to about 6O 0 C, or from about 50 to about 56 0 C.
  • the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, about 56 0 C.
  • greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.
  • lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. Such rates, however, may still be suitable, given the ease with which this hydrolysis occurs.
  • the reaction mixture may be maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In such embodiments, the temperature tends to increase once the acid has been charged to the reactor.
  • This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
  • the reaction time will depend on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion.
  • the reaction time may be less than a minute, essentially spontaneous, or spontaneous. Generally, however, the reaction time is at least about 1 minute, more typically at least about 5 minutes, and still more typically at least about 15 minutes. Normally, the reaction time is less than about 3 hours. In some embodiments, for example, the reaction time is from about 0.25 to about 2 hours, from about 0.25 to about 1.5 hours, or from about 0.25 to about 1.1 hours. Although lesser reaction times may be used, such reaction times may coincide with lesser conversions.
  • reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
  • Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
  • the macrolide synthesis begins by or includes preparing a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure for Formula (V):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; or R 1 and R 3 are each hydrogen, and R 2 is methyl. In other embodiments, R 1 , R 2 , and R 3 are each hydrogen:
  • the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound may be prepared via an acid hydrolysis reaction from a 23-O-mycinosyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound:
  • the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound used in the above reaction may be prepared using a process discussed above in Section B-2, prepared using a different process, or obtained from a commercial vendor.
  • the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound is prepared using a process discussed above in Section B-2.
  • the acid may, for example, be a strong mineral acid, such as hydrochloric acid, nitric acid, fluoroboric acid, sulfuric acid, phosphoric acid, polyphosphonic acid, or hydrobromic acid; or a strong organic acid, such as/?-toluenesulfonic acid or trifluoroacetic acid.
  • the acid comprises HCl.
  • the acid comprises HBr. As with the hydrolysis discussed above in Section B-2, this preference stems from the tendency of HBr to coincide with a less amount of impurities in the product mixture relative to, for example, HCl.
  • a mixture of acids is used.
  • the acids used in the mycinosyloxy and mycarosyloxy hydrolysis reactions may be different, although it is generally more preferred for the acids to be the same. In some embodiments, for example, HCl is used in both reactions. In other embodiments, HBr is used in both reactions.
  • sufficient acid is mixed with the 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound to hydro lyze the mycinosyloxy substituent to form a hydro xyl group.
  • the amount of acid will be greater than about one equivalent, based on the molar amount of 23-O-mycinosyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
  • the acid is added to the reaction mixture in the form of a concentrated composition.
  • the concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30% (mass/vol), or from about 1 to about 24% (mass/vol).
  • the acid is HBr
  • concentration of the acid solution added to the reaction mixture is about 24% (mass/vol).
  • the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.
  • the ingredients may generally be charged to the reactor in any sequence.
  • the reactor may comprise various reactor types.
  • the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the acidic reaction mixture may be used.
  • the mixture normally is maintained at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous.
  • the reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is not greater than the boiling point of the solvent (e.g., water), and typically is less than the boiling point.
  • the solvent e.g., water
  • At least a portion of the reaction is conducted at a temperature of at least about 1O 0 C, greater than about 25 0 C, or at least about 48 0 C.
  • the reaction temperature over at least a portion of the reaction (or the entire reaction) typically is not greater than about 100 0 C, or not greater than about 65 0 C. In some embodiments, for example, the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 10 to about 100 0 C. In some embodiments when the acid is HCl or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is from about 48 to about 6O 0 C.
  • the temperature over at least a portion of the reaction (or the entire reaction) is from about 55 to about 6O 0 C. In other such embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 51 to about 57 0 C (e.g., about 54 0 C). In still other such embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 50 to about 56 0 C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.
  • the mycinosyloxy hydrolysis reaction mixture may be maintained at a temperature that is slightly less than the desired reaction temperature while at least a portion of the acid (or all the acid) is being charged to the reactor.
  • This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
  • the reaction time depends on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion.
  • the reaction time is generally at least about 1 minute, and more typically at least about 15 minutes.
  • the reaction time is less than about 7 hours.
  • the reaction time is from about 0.5 to about 7 hours.
  • the reaction time is from about 1 to about 5 hours, or from about 3 to about 5 hours.
  • lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions.
  • greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
  • the two reactions may be carried out as two discrete steps or as a single reaction.
  • the reaction mixture may be maintained at the same temperature or changed (typically increased) over time. If the reaction mixture is maintained at the same temperature, the mixture normally is maintained at a temperature of at least about 1O 0 C, typically greater than about 25 0 C, more typically at least about 3O 0 C, and still more typically at least about 45 0 C. In some embodiments, the temperature is maintained at from about 10 to about 100 0 C.
  • the temperature is from about 48 to about 7O 0 C. In other such embodiments, for example, the temperature is from about 50 to about 56 0 C. In other such embodiments, for example, the temperature is from about 55 to about 6O 0 C. In still other such embodiments, the temperature is from about 65 to about 7O 0 C. If the temperature of the mixture is increased over time, the temperature of the mixture at the beginning of the hydrolysis normally is at least about 15 0 C, or at least about 25 0 C.
  • the temperature preferably is increased to at least about 3O 0 C, at least about 45 0 C, or from about 48 to about 7O 0 C.
  • the increased temperature is from about 50 to about 56 0 C.
  • the increased temperature is from about 55 to about 6O 0 C.
  • the increased temperature is from about 65 to about 7O 0 C.
  • the reaction mixture is maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In those embodiments, the temperature tends to increase once the acid has been charged to the reactor.
  • the total reaction time when the two hydrolysis reactions are combined depends on various factors including, for example, reaction temperature, relative amounts of the ingredients, and the desired conversion. Generally, however, the reaction time for the combined hydrolysis reactions in a batch reactor is at least about 4 hours. In some embodiments, the combined reaction time is from about 4 to about 6 hours. In some such embodiments, for example, the combined reaction time is about 4 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is from about 65 to about 7O 0 C. In other embodiments, the reaction time is about 5 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is from about 55 to about 6O 0 C.
  • Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
  • the macrolide synthesis begins by or includes preparing an activated compound, and particularly a compound that corresponds in structure to Formula (VI):
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; or R 1 and R 3 are each hydrogen, and R 2 is methyl. In other embodiments, R 1 , R 2 , and R 3 are each hydrogen, such that the compound corresponds in structure to:
  • L is a leaving group.
  • the leaving group is a group that may be replaced with a piperidinyl group (normally via nucleophilic displacement) using piperidine in an amination reaction, such as the amination reaction discussed below in Section B-5.
  • L is iodo (-1), bromo (-Br), alkylsulfonate, and arylsulfonate.
  • the alkylsulfonate and arylsulfonate are optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, and haloalkyl.
  • L is iodo, bromo, methylsulfonate (or “-OS(O) 2 CHs” or “mesylate”), trifluoromethylsulfonate (or “-OS(O) 2 CF 3 " or “trifiate”), or 4-methylphenylsulfonate (or >-toluenesulfonate” or “tosylate”).
  • L is iodo, and the activated compound corresponds in structure to: or, when R 1 , R 2 , and R 3 are each hydrogen, corresponds in structure to:
  • L is mesylate
  • the activated compound corresponds in structure to:
  • R 1 , R 2 , and R 3 each are hydrogen, corresponds in structure to:
  • L is tosylate
  • the activated compound corresponds in structure to: or, when R 1 , R 2 , and R 3 each are hydrogen, corresponds in structure to:
  • L is triflate
  • the activated compound corresponds in structure to:
  • R 1 , R 2 , and R 3 each are hydrogen, corresponds in structure to:
  • the activated compound may be prepared via an activation reaction from a IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound and an activating agent (i.e., a compound comprising an electron withdrawing group):
  • the IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound used in the above reaction may be prepared using a process discussed above in Section B- 3, prepared using a different process, or obtained from a commercial vendor.
  • the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound is prepared using a process discussed above in Section B-3.
  • L is iodo
  • the activating agent is formed by mixing I 2 and triphenylphosphine:
  • this reaction is conducted in the presence of one or more solvents.
  • the solvent is non-reactive with the reagents, products, and any other ingredients in the reaction mixture (although, as noted below, the solvent may, for example, act as a helping base).
  • the solvent may be, for example, one or more of dichloromethane ("DCM"), acetone, acetonitrile (“ACN”), tert-butyl methyl ether (or “tBME”), toluene, and pyridine.
  • DCM dichloromethane
  • ACN acetone
  • tBME tert-butyl methyl ether
  • THF tetrahydrofuran
  • the solvent comprises pyridine, which also may act as a helping base.
  • the solvent comprises dichloromethane.
  • the solvent comprises both dichloromethane and toluene.
  • the ratio of dichloromethane to toluene is, for example, be at least about 1 :1, from about 3:1 to about 10 : 1 , or from about 3 : 1 to about 5:1.
  • at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, dissolve the reagents (particularly the 23-hydroxyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound), and promote homogenous distribution of the reagents.
  • the amount of solvent typically is at least about 1 L per kilogram of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the amount of solvent typically is not greater than about 100 L per kilogram of the 23- hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the amount of solvent is from about 5 to about 20 L (or from about 5 to about 15 L, or from about 10 to about 12 L) per kilogram of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
  • the amount of solvent is about 10 L DCM per kilogram.
  • the amount of solvent is about 12 L DCM per kilogram.
  • the solvent is a mixture of DCM and toluene (about 4:1 vol/vol), and the amount of solvent is about 10 L per kilogram.
  • this reaction may be conducted in the presence of a base (or "helping base”).
  • the base may be a single base, or a combination of bases.
  • This base may comprise, for example, triethylamine, pyridine, imidazole, potassium carbonate, and/or 4-dimethylaminopyridine (or "DMAP").
  • the presence of the base may increase the reaction rate.
  • the base comprises pyridine.
  • the activating agent comprises I 2 and triphenylphosphine.
  • the base comprises imidazole.
  • the base comprises a combination of potassium carbonate and 4-dimethylaminopyridine.
  • the activating agent comprises /?-toluenesulfonyl chloride.
  • the helping base is attached to a solid support (e.g., a resin).
  • the molar amount of the base is typically at least equivalent to the molar amount of IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound.
  • the amount of the base is at least 1.05 equivalents.
  • the molar amount of the base is from about 1.1 to about 10 equivalents, from about 1.1 to about 5 equivalents, or from about 1.1 to about 3 equivalents.
  • the molar amount of base is from about 1.1 to about 1.4 equivalents (e.g., about 1.15 or about 1.3 equivalents). In other such embodiments, the molar amount of the base is about 2.8 equivalents.
  • the total molar amount of base preferably falls within the ranges described above.
  • the source of the activating agent comprises /?-toluenesulfonyl chloride
  • an example of a contemplated amount of base is about 1.5 equivalents of potassium carbonate and about 1.0 equivalents of 4-dimethylaminopyridine, based on the amount of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the source of the activating agent is I 2 and triphenylphosphine
  • the I 2 , triphenylphosphine, and base are typically first combined in the presence of solvent to form the activating agent before they are combined with the 23-hydroxyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the reactor in which the activating agent is formed may be the same reactor in which the activating agent is combined with the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • the activating agent may be formed in a different reactor, and then charged to the reactor to which the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound is charged.
  • the I 2 may be added in one or more doses to the triphenylphosphine or vice versa.
  • the I 2 is added to the triphenylphosphine in two or more portions (e.g., 5 portions) or vice versa. The portions may be equal or different amounts.
  • the combination of the I 2 and triphenylphosphine takes place in the presence of a solvent, which may, for example, comprise the solvent(s) that is used in the substitution reaction.
  • a base e.g., pyridine
  • the mixture preferably is maintained at from about 15 to about 35 0 C (or from about 20 to about 3O 0 C, e.g., about 25 0 C) during the addition of I 2 to the triphenylphosphine, and then maintained at a temperature of from about 15 to about 35 0 C (or from about 20 to about 3O 0 C, e.g., about 25 0 C) after the addition for at least about one minute (e.g., about 2 minutes), or for at least about 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., about 40 minutes).
  • the temperature preferably is adjusted to a temperature that is approximately equal to the temperature at which the substitution reaction is to be initiated.
  • equimolar amounts of the 23- hydroxyl ⁇ O-piperidinyl-S-O-mycaminosyl-tylonolide compound and activating agent generally may be used. Normally, however, an excess of the activating agent is used, and typically at least 1.05 equivalents are used, based on the molar amount of 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound.
  • the molar amounts of I 2 and triphenylphosphine are each at least 1.05 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound.
  • the molar amounts of I 2 and triphenylphosphine are each from 1.05 to about 10 equivalents, from 1.05 to about 5 equivalents, or from 1.05 to about 3 equivalents.
  • I 2 and triphenylphosphine typically exceeds the equivalents of I 2 .
  • suitable molar amounts of I 2 and triphenylphosphine may be about 2.5 and 2.6 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • suitable molar amounts of I 2 and triphenylphosphine are about 1.9 and 2.0 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
  • a suitable molar amount of I 2 is from 1.05 to about 1.2 equivalents, based on the molar amount of 23-hydroxyl-20- piperidinyl-5-O-mycamino syl-tylono lide compound; and a suitable amount of triphenylphosphine is from about 1.09 to about 1.25 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound.
  • suitable molar amounts of I 2 and triphenylphosphine may be about 1.06 and about 1.13 equivalents, respectively, based on the molar amount of 23-hydroxyl-20- piperidinyl-5-O-mycamino syl-tylono lide compound.
  • suitable molar amounts of I 2 and triphenylphosphine may alternatively be about 1.2 and about 1.25 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
  • the molar amount ofp-toluenesulfonyl chloride is from about 1.1 to about 10 equivalents, from about 1.2 to about 5 equivalents, or from about 1.2 to about 3 equivalents, based on the molar amount of IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound.
  • a suitable molar amount of /?-toluenesulfonyl chloride may be, for example, 1.2 equivalents.
  • substitution reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
  • the reaction temperature for at least a portion of the substitution reaction typically is greater than the freezing point of the solvent.
  • the reaction temperature over at least a portion of the substitution (or the entire substitution) is not greater than the boiling point of the solvent, and typically is less than the boiling point.
  • the solvent is dichloromethane, and at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 45 0 C. In some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 32 0 C, or not greater than about 25 0 C.
  • At least a portion of the reaction is conducted at from about -1O 0 C to about 25 0 C.
  • at least a portion of the reaction (or the entire reaction) is conducted at from about zero to about 2O 0 C, or from about 12 to about 18 0 C (e.g., about 13 0 C).
  • at least a portion of the reaction (or the entire reaction) is conducted at from about -1O 0 C to about 45 0 C, or from about 25 to about 45 0 C.
  • At least a portion of the reaction is conducted at from about -10 to about O 0 C, or from about -6 to about -5 0 C.
  • lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates.
  • greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.
  • Use of some sources of the activating agent e.g., toluenesulfonyl chloride
  • greater temperatures to be used e.g., from about 25 to about 45 0 C).
  • the activating agent is iodine
  • the reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion.
  • the total reaction time is typically at least about 1 minute, and more typically at least about 45 minutes. In general, the total reaction time is less than about 24 hours. In some embodiments, for example, the total reaction time is less than about 5 hours. To illustrate, in some embodiments, the reaction time is from about 45 minutes to about 5 hours, or from about 1 to about 3 hours. In some such embodiments, for example, the reaction time is from about 2 to about 3 hours, or from about 2 to about 2.5 hours (e.g., about 2 or about 2.2 hours).
  • the reaction time is from about 5 to about 10 hours, from about 6 to about 10 hours, from about 7 to about 10 hours, or from about 7 to about 8 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
  • the 23-hydroxyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound is combined with the activating agent over time (or in multiple separate doses) rather than all at once. In some embodiments, this occurs over a period of at least one minute, at least 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., about 50 minutes).
  • the substitution reaction is conducted at a maximum temperature of about 25 0 C, and the dosing of the activating agent occurs over from about 0.5 to about 1 hour, followed by an additional reaction time of about 1 hour. In other embodiments, the substitution reaction is conducted at a maximum temperature of about -5 0 C, and the dosing of the activating agent occurs over from about 0.7 to about 1 hour, followed by an additional reaction time of about 7 hours.
  • the substitution reaction is quenched to inactivate any residual iodine, and, therefore, reduce (and preferably prevent) by-product formation due to such residual iodine.
  • the reaction is quenched with aqueous sodium sulfite (i.e., Na 2 SOs). Purification or isolation of the product may be achieved using, for example, various methods known in the art.
  • the product may be used in the next step without further purification or isolation.
  • Both the activating agent formation reaction and the substitution reaction may be conducted in various reactor types.
  • the reactor is a stirred-tank reactor.
  • the reactor may be made of any composition that remains stable when exposed to the reaction mixture.
  • Such materials include, for example, various materials, such as glass (including glass-lining) or stainless steel.
  • R 1 and R 3 are each methyl, and R 2 is hydrogen; R 1 and R 3 are each hydrogen, and R 2 is methyl; or R 1 , R 2 , and R 3 are each hydrogen.
  • R 4 and R 6 are each methyl, and R 5 is hydrogen; R 4 and R 6 are each hydrogen, and R 5 is methyl; or R 4 , R 5 , and R 6 are each hydrogen.
  • R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each hydrogen:
  • the preparation of the macro lide begins by or includes an amination reaction of an activated compound with a piperidinyl compound:
  • the activated compound used in the above reaction may be prepared using a process discussed above in Section B-4, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the activated compound is prepared using a process discussed above in Section B-4.
  • this reaction is conducted in the presence of one or more solvents.
  • the solvent is non-reactive with the reagents (e.g., the activated compound), products, and any other ingredients in the reaction mixture.
  • the solvent may be, for example, acetonitrile (or "CH3CN”); chloroform; dichloromethane; tetrahydrofuran; a ketone solvent, such as acetone (or "CH 3 COCH 3 "); a hydrocarbon solvent, such as an aromatic hydrocarbon solvent (e.g., toluene or xylene); or a base, such as pyridine or piperidine.
  • the solvent comprises acetonitrile.
  • the solvent comprises tetrahydrofuran. In some embodiments, the solvent comprises dichloromethane. In some embodiments, the solvent comprises xylene. In some embodiments, at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the activated compound.
  • the amount of solvent can vary widely, from no solvent at all to amounts that create diluted reaction mixtures. Typically, the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents. In some embodiments, sufficient solvent is present such that the combined amount of activating reagent and macro lide is from about 5 to about 50% (mass/volume) of the reaction mixture. In some embodiments, the amount of solvent is at least about 1 L per kilogram activated compound. In some such embodiments, for example, the amount of solvent is from about 1 to about 100 L (or from about 1 to about 20 L) per kilogram of activated compound.
  • solvent e.g., xylene or tetrahydrofuran
  • solvent e.g., acetonitrile
  • the amination is conducted in the presence of a base.
  • the base comprises an un-hydrated base.
  • the base may be, for example, potassium carbonate (or "K2CO3"), sodium carbonate (or "Na 2 COs”), or a tertiary amine.
  • K2CO3 potassium carbonate
  • Na 2 COs sodium carbonate
  • a tertiary amine a tertiary amine.
  • the base preferably is not so strong as to cause hydrolysis of the lactone in the macro lide core. Generally, equimolar amounts of the activated compound and base may be used. Normally, however, an excess of base is used.
  • At least 1.05 (or from about 1.1 to about 50, from about 2 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of base are used, based on the molar amount of activated compound charged to the reactor.
  • about 6.2 equivalents of base are used.
  • about 10 equivalents of base are used.
  • from about 1.1 to about 10 (or from about 2 to about 8, or from about 4 to about 6) equivalents of base are used, based on the molar amount of activated compound charged to the reactor.
  • a suitable amount of base may be, for example, about 5 equivalents.
  • the activated compound, piperidinyl compound, and solvent, as well as any base are normally charged to a reactor and mixed. These ingredients generally may be charged to the reactor in any sequence.
  • the reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass, glass-lined, and stainless steel reactors are often preferred, although any composition stable when exposed to the reaction mixture may be used.
  • equimolar amounts of the activated compound and piperidinyl compound may be used. Normally, however, an excess of the piperidinyl compound is used. In some embodiments, at least 1.05 (or from about 1.1 to about 50, from about 2 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of the piperidinyl compound are used, based on the molar amount of activated compound charged to the reactor. In some such embodiments, about 10 equivalents of the piperidinyl compound are used. In other such embodiments, from about 2 to about 8 (or from about 4 to about 6) equivalents are used, based on the molar amount of activated compound charged to the reactor. To illustrate, a suitable amount of piperidinyl compound may be, for example, about 4.7 equivalents. A contemplated suitable amount of piperidinyl compound also may be, for example, about 5.7-5.8 equivalents.
  • At least a portion of the reaction normally is conducted at greater than about 2O 0 C, or greater than about 25 0 C.
  • the optimal reaction temperature depends on, for example, the solvent.
  • at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and typically is less than the boiling point.
  • at least a portion of the reaction (or the entire reaction) is conducted at from about 50 to about HO 0 C.
  • at least a portion of the reaction (or the entire reaction) is conducted at from about 60 to about HO 0 C, or from about 75 to about HO 0 C.
  • a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 78 0 C to about HO 0 C (e.g., about 78 0 C).
  • a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 95 to about 105 0 C, and a suitable reaction time for the reaction is about 15 hours.
  • the solvent comprises tetrahydrofuran, and at least a portion of the reaction (or the entire reaction) is conducted at from about 55 to about 75 0 C.
  • the amination reaction is conducted at more than one temperature.
  • the reaction may be conducted at one temperature initially, and then slowly increased to another temperature as the reaction progresses.
  • the amination may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
  • the reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion.
  • the reaction time is generally at least about 1 minute, at least about 5 minutes, or at least about 45 minutes.
  • the reaction time is generally no greater than about 24 hours.
  • the reaction time is from about 2 to about 15 hours.
  • the reaction time is from about 1 to about 5 hours, from about 2 to about 4 hours, or from about 2 to about 3 hours (e.g., about 2.5 hours).
  • the reaction time is from about 6 to about 15 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions.
  • This invention contemplates any processes that use any of the above reactions.
  • the process will comprise one of the above reactions.
  • the process will comprise two, three, four, or all the above reactions.
  • Scheme I generically illustrates a scenario where all the above reactions are used:
  • R 1 and R 3 are each methyl, and R 2 is hydrogen;
  • R 1 and R 3 are each hydrogen, and R 2 is methyl; or
  • R 1 , R 2 , and R 3 are each hydrogen.
  • R 4 , R 5 , and R 6 are each hydrogen.
  • R 4 and R 6 are each methyl, and R 5 is hydrogen;
  • R 4 and R 6 are each hydrogen, and R 5 is methyl; or
  • R 4 , R 5 , and R 6 are each hydrogen.
  • L is a leaving group.
  • the tylosin reagent used in the processes of this invention comprises tylosin A (or a salt thereof):
  • Tylosin A Although this invention contemplates the use of pure (or at least essentially pure) tylosin A (or a salt thereof), various commercially available tylosin compositions additionally or alternatively may comprise one or more derivatives of tylosin A, including:
  • tylosin B also known as desmycocin
  • tylosin C also known as macrocin
  • tylosin D also known as relomycin.
  • the weight ratio of tylosin A to the total combined amount of tylosin A derivatives in the composition is at least about 1 :1. In some such embodiments, for example, the ratio is at least about 4:1, at least about 10:1, at least about 95:5, at least about 98:2, or at least about 99:1. In other such embodiments, about 100% (by weight) of the tylosin compounds (i.e., tylosin A and tylosin A derivatives) in the composition consists of tylosin A.
  • the tylosin A makes up less than 50% (by weight) of the tylosin compounds in the composition.
  • the weight ratio of tylosin D to the total combined amounts of tylosin A and other tylosin A derivatives is at least about 1 : 1 , at least about 4: 1 , at least about 9:1, at least about 95:5, at least about 98:2, or at least about 99:1.
  • about 100% (by weight) of the tylosin compounds in the composition consists of tylosin D.
  • Tylosin B for example, has a hydroxyl instead of a mycarosyl substituent on the 5-mycanimosyl.
  • a 20-piperidinyl intermediate derived from tylosin B does not require the first hydrolysis reaction discussed above in Section B-2. To the extent such an intermediate is exposed to the hydrolysis method discussed in Section B-2, the intermediate will generally remain non-reactive or begin hydro lyzing at the 23- mycinosyloxy substituent.
  • Tylosin C has a hydroxyl rather than a methoxy at the 3-position of the 23- mycinosyloxy substituent. This difference generally has no effect with respect to the above-described methods.
  • the sugar normally will cleave (i.e., hydro lyze) in the same manner and under the same conditions as the 23-mycinosyloxy of tylosin A during the hydrolysis described above in Section B-3.
  • Tylosin D has a hydroxyl rather than a carbonyl at the 20-position. This hydroxyl is generally not transformed into a piperidinyl using the reductive amination method described above in Section B-I. Depending on the reaction conditions, however, it may become activated during the activation reaction described above in Section B-4, and then aminated with piperidine along with the 23 -position during the amination method described above in Section B-5.
  • Salts of Intermediates and Macrolides This invention may be used to prepare macro lide compounds or intermediates both in the form of free compounds and in the form of salts.
  • the reagents used in this invention may be in the form of salts.
  • Salts may be, for example, acid addition salts.
  • an acid addition salt can be prepared using any inorganic or organic acid.
  • a salt of a compound may be advantageous due to one or more of the salt's chemical or physical properties, such as stability in differing temperatures and humidities, or a desirable solubility in water, oil, or other solvent.
  • a salt of a compound also may be used as an aid in the isolation or purification of a compound.
  • the salt is pharmaceutically acceptable.
  • Salts can typically be formed by, for example, mixing the free macro lide or intermediate compound with an acid using various known methods in the art.
  • inorganic acids include hydrochloric, hydrobromic, hydro iodic, nitric, carbonic, sulfuric, and phosphoric acid.
  • organic acids include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • organic salts include cholate, sorbate, laurate, acetate, trifluoroacetate (or "CF3COOH” or “TFA”), formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartrate (and derivatives thereof, such as dibenzoyltartrate), citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate (and derivatives thereof), embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2- hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, ⁇ -hydroxybutyric acid, galact
  • the macrolides prepared by the above-described processes may generally be used, for example, to treat pasteurellosis in animals, particularly livestock and poultry.
  • a macrolide(s) is used to treat bovine animals having bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
  • BBD bovine respiratory disease
  • such a macro lide(s) is used to treat swine animals having swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Bordetella bronchiseptica.
  • a therapeutically-effective amount of one or more of such macro lides is administered to the recipient animal.
  • the term "therapeutically effective amount” constitutes an amount that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection.
  • the therapeutically effective amount is defined as the amount necessary to achieve a concentration efficacious to control the target pathogen(s) at the site of infection (or, when used to prevent, reduce the risk of, or delay the onset of infection, at a site susceptible to infection).
  • the concentration at the site of infection is preferably at least equal to the MIC90 level (minimum inhibitory concentration, i.e., the concentration that inhibits the growth of 90% of the target pathogen) of the macrolide for the target pathogen.
  • MIC90 level minimum inhibitory concentration, i.e., the concentration that inhibits the growth of 90% of the target pathogen
  • Such an amount may be administered to the animal recipient in two or more separate doses, although preferably is administered in a single dose.
  • the term "therapeutically effective amount” refers to the total amount of the macro lide(s) combined with the other active ingredient(s) that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection.
  • Factors affecting the preferred dosage regimen include the type ⁇ e.g., species and breed), age, weight, sex, diet, activity, and condition of the animal recipient; the severity of the pathological condition; the apparatus used to administer the composition, as well as the type of administration used; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular composition administered; the existence of an additional active ingredient(s) in the composition; and whether the composition is being administered as part of a drug and/or vaccine combination.
  • the dosage actually employed can vary for specific animal patients, and, therefore, can deviate from the typical dosages set forth above. Determining such dosage adjustments is generally within the skill of those in the art using conventional means.
  • the macro lide(s) may be administered once to an animal, although it is contemplated that it may instead be administered multiple times.
  • the total amount of administered macrolide(s) is typically from about 0.1 to about 40 mg per kg body weight, and more typically from about 1 to about 10 mg per kg body weight. For example, in some embodiments, the amount administered to cattle is about 4 mg per kg body weight.
  • the macro lide(s) may be given to cattle at any age, in some embodiments, the macro lide(s) is administered to cattle that are from about 1 months to about 1.5 years old, or from about 6 months to about 1 year old. In some embodiments, the macro lide(s) is administered to weaned calves entering the feedlots (often at about 6 months old).
  • the cattle are calves at from about 2 to about 12 weeks old, and the macro lide(s) is administered for prophylaxis at a dosage of from about 1 to about 10 mg per kg of the body weight; or for treating an existing infection at a dosage of from about 2 to about 20 mg per kg of the body weight.
  • the total amount of administered macrolide(s) is typically from about 0.1 to about 50 mg per kg body weight, and more typically from about 1 to about 10 mg per kg body weight.
  • the amount administered to swine is about 4 mg per kg body weight.
  • the amount administered to swine is about 5 mg per kg body weight.
  • the macro lide(s) may be given to swine at any age, in some embodiments, the macro lide(s) is administered to grower- finisher pigs.
  • the method of administration can be varied depending on animals, but in the case of large mammals such as cattle, swine, and horses, it is preferably administered orally or parenterally.
  • Parenteral administration includes, for example, subcutaneous injections, intravenous injections, intramuscular injections, intrasternal injections, submucosal injections, and infusion.
  • the animal recipient is a bovine animal, and the macro lide composition is administered subcutaneously, such as in the neck.
  • the animal recipient is a swine animal, and the macrolide composition is administered intramuscularly.
  • the macrolide(s) may be used to form a pharmaceutical composition (or "medicament"). It is contemplated that such a composition may entirely comprise one or more macro lides. Normally, however, the composition comprises other ingredients as well. [124] Other ingredients in the composition may comprise, for example, other active ingredients. Alternatively (or in addition), such other ingredients may comprise one or more pharmaceutically acceptable carriers, vehicles, and/or adjuvants (collectively referred to as "excipients").
  • Solid macrolide compositions may comprise, for example, saccharides such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose derivatives, such as carboxymethylcellulose sodium, ethylcellulose, and cellulose acetate; etc.
  • Liquid macrolide compositions may comprise for example, water, isotonic physiological saline, Ringer's solution, ethyl alcohol, and/or phosphate buffer solution may be present.
  • Such compositions also may comprise oils, such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil and/or polyhydric alcohols such as glycerol, propylene glycol, sorbitol, mannitol, polyethylene glycol, and poly(ethylene glycol-2-propylene glycol-2-poly ethylene glycol). It also, for example, may be desirable in some instances for the composition to comprise one or more preservatives.
  • a preservative may, for example, provide a benefit for compositions or solvents that may be stored over lengthy periods of time, e.g., days, weeks, months, or years.
  • factors to consider include, for example, its antimicrobial activity; the pH range at which it has the desired antimicrobial activity; the minimum concentration at which it has the desired antimicrobial activity; its aqueous solubility and other physical characteristics (e.g., potential to cause foaming); its suitability for parenteral use; its possible interactions with the active ingredient(s) (e.g.
  • Contemplated preservatives include, for example, parabens, propylene glycol, benzalkonium chloride, phenylethanol, chlorocresol, metacresol, ethanol, phenoxyethanol, and benzyl alcohol.
  • the macrolide composition may be suitable for the macrolide composition.
  • suitable excipients may include, for example, coloring agents; flavoring agents; and thickening agents, such as povidone carboxymethylcellulose, and/or hydroxypropyl methylcellulose.
  • the macro lide(s) occupies at least about 0.5% by weight of the pharmaceutical composition.
  • suitable macro lide concentrations for parenteral administration may be, for example, from about 5 to about 500 mg/ml, from about 10 to about 100 mg/ml, or from about 20 to about 60 mg/ml (e.g., about 40 mg/ml).
  • suitable macrolide concentrations for parenteral administration may be, for example, from about 5 mg/ml to about 2.0 g/ml, from about 10 mg/ml to about 1.0 g/ml, 50 to about 500 mg/ml, or from about 100 to about 300 mg/ml (e.g., 180 mg/ml).
  • the macrolide concentration can be varied depending on the dosage form. Where, for example, the macro lide(s) is administered parenterally, the macrolide concentration preferably is sufficient to provide the desired therapeutically effective amount of the macro lide(s) in a volume that is acceptable for parenteral administration.
  • the maximum acceptable volume may vary, depending on, for example, the apparatus being used for the administration, type of parenteral administration, size of the recipient animal, and subjective desires of the user.
  • kits that are, for example, suitable for use in performing the methods of treatment described above.
  • the kit comprises a therapeutically effective amount of at least one of the above-described macro lides, and instructions for combining the macrolide(s) with at least one excipient, such as, for example, instructions for dissolving or suspending the macrolide(s) in a liquid excipient.
  • the kit may further (or alternatively) comprise additional components, such as, for example, one or more apparatuses (e.g., a syringe) for administering a composition comprising (or derived from) the macrolide(s), one or more additional pharmaceutical or biological materials, one or more excipients, and/or one or more diagnostic tools.
  • additional components such as, for example, one or more apparatuses (e.g., a syringe) for administering a composition comprising (or derived from) the macrolide(s), one or more additional pharmaceutical or biological materials, one or more excipients, and/or one or more diagnostic tools.
  • Example 1 Preparation of 20,23-dipiperidinyl-5-O-mycaminosyl- tylonolide from tylosin A.
  • tylosin A (1) (3.68 kg; >80% tylosin A; >95% tylosin A, B, C, & D), piperidine (0.40 kg), and formic acid (0.55 kg) were charged to a reactor.
  • the mixture was heated to 70-80 0 C, while being stirred. Stirring was then continued at that temperature for 1-2 more hours.
  • the formation of the 20-piperidinyl-tylosin compound (2) was monitored by HPLC. After reaction completion ( ⁇ 2% tylosin A (I)), the product mixture was cooled to ambient temperature.
  • HBr (48% HBr diluted to 24%) was added to the product mixture of Part A while stirring and maintaining the mixture at less than 4O 0 C. Afterward, the phases in the product mixture were separated using a 20-minute phase separation period. The product mixture was at 20-25 0 C during this phase separation. HPLC of the lower phase was used to confirm reaction completion ( ⁇ 2% 20-piperidinyl-tylosin compound (2)).
  • HBr Twenty- four percent HBr (18.4 L) was added at ambient temperature to the aqueous phase obtained from Part B, followed by heating to 54 ⁇ 3 0 C within about 1 hour while stirring. Stirring was continued at this temperature for 2-4 more hours, while the reaction was monitored using HPLC. After completion of the reaction ( ⁇ 2% 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound (3)), the mixture was cooled to ambient temperature using a -1O 0 C cooling jacket. After cooling, the mixture was extracted with dichloro methane three times (9.8 kg each time). The aqueous product was cooled to 4-8 0 C, and then 6 N NaOH (33.6 kg) was slowly added to adjust the pH to >10.
  • Triphenylphosphine (0.9 kg) and pyridine (0.3 kg; free of water) were dissolved into dichloromethane (11.7 kg) at ambient temperature. Iodine (0.8 kg) was then added. The resulting mixture was then stirred until all the iodine dissolved. The mixture was then cooled to 13 0 C. The cooled mixture was added to the product from Part C in dichloromethane (11.7 kg) while stirring at 15 ⁇ 3 0 C. The reaction was monitored by HPLC, and was determined to be completed in 2-2.5 hours ( ⁇ 2% 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound) .
  • the phases were separated at ambient temperature, and the lower aqueous phase was extracted three times with ethyl acetate (15.8 kg were used each time).
  • the resulting aqueous phase was set to a pH of 11 by addition of 6 N NaOH (6.4 kg) and extracted three times with dichloromethane (18.7 kg each time) at ambient temperature.
  • the combined lower organic phases were recharged to the reactor with sodium sulfate (5.3 kg).
  • the mixture was then filtered to form a cake, which, in turn, was washed with dichloromethane (4.9 kg) and dried under vacuum at a jacket temperature of 5O 0 C to form a macro lide product.
  • This product was mixed with acetonitrile (21.7 L) and re-crystallized.
  • the resulting crystals were isolated on a Nutsch filter, washed twice with cold acetonitrile (3.5 L each time), and dried under vacuum at 4O 0 C overnight to form macro lide (5) product.
  • Tylosin phosphate (1) and dichloromethane (1.3 L per kg tylosin phosphate) were charged to a reactor. The resulting mixture was stirred to produce a clear solution.
  • piperidine (1.2 eq, based on the tylosin phosphate), formic acid (4.5 eq, based on the tylosin phosphate), and toluene (6.7 L per kg tylosin phosphate) were sequentially charged to the reactor.
  • the resulting mixture was heated to 76 0 C while being stirred. Stirring was then continued at that temperature for 2.5 hours.
  • Additional piperidine (0.1 eq, based on the tylosin phosphate) was then charged, and the resulting mixture was stirred at 76 0 C for an additional hour.
  • the product mixture was cooled to 5O 0 C.
  • the aqueous phase was extracted twice with dichloromethane at 25-3O 0 C.
  • the aqueous phase was then cooled to O 0 C, and the pH was adjusted to 10-10.5 with NaOH at ⁇ 5°C.
  • the aqueous phase was extracted twice with dichloromethane at 2O 0 C.
  • the resulting combined organic phases were extracted twice with aqueous NaHCO 3 .
  • the dichloromethane was then removed from the combined organic phases via distillation, and replaced with isopropyl alcohol.
  • heptane at 45 0 C was added to initiate precipitation.
  • the mixture was then stirred at O 0 C.
  • the crystalline product was isolated by filtration. The isolated crystals were washed with heptane and isopropyl alcohol, dried, and analyzed using HPLC.
  • Triphenylphosphine (0.41 kg per kg of product of Part B) was dissolved in dichloromethane (12 L per kg of triphenylphosphine, ⁇ 100 ppm H 2 O) at 25 0 C. Pyridine (0.3 kg per kg triphenylphosphine) was then added. Next, iodine (0.9 kg per kg of triphenylphosphine) was added in 5 portions at 25 0 C. The resulting mixture was stirred for 40 minutes at 25 0 C, and then cooled to -6 0 C. The mixture was then added to the product from Part B over 50 minutes while stirring at -6 0 C. Afterward, stirring was continued for 7 hours while maintaining the mixture at -5 0 C.
  • the term "pharmaceutically acceptable” is used adjectivally in this patent to mean that the modified noun is appropriate for use in a pharmaceutical product.
  • pharmaceutically acceptable when it is used, for example, to describe an excipient or a salt, it characterizes the excipient or salt as having a benef ⁇ t(s) that outweighs any deleterious effect(s) that the excipient or salt may have to the intended recipient animal.
  • ambient temperature means a temperature of from about 20 to about 25 0 C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl- tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides.

Description

MACROLIDE SYNTHESIS PROCESS
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[1] This patent claims priority to U.S. Provisional Patent Application No. 60/834,067 (filed July 28, 2006); and European Patent Application No. 06118159.0 (filed July 31, 2006). The entire text of both those patent applications is incorporated by reference into this patent.
FIELD OF THE INVENTION
[2] This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide and derivatives thereof, as well as methods of treatment using such macrolides, uses of such macrolides to make medicaments, and methods for making intermediates that, inter alia, may be used to make macrolides.
BACKGROUND OF THE INVENTION
[3] Macrolides have long been known to be effective for treating infectious diseases in humans, livestock, poultry, and other animals. Early macrolides included 16- membered macrolides such as, for example, tylosin A:
Figure imgf000002_0001
See, e.g., U.S. Patent No. 4,920,103 (col. 5, lines 12-38). See also, U.S. Patent No. 4,820,695 (col. 7, lines 1-32) and EP 0103465B1 (page 5, line 3). Over the years, various tylosin derivatives have been developed with the goal of enhancing antibacterial activity and selectivity.
[4] Tylosin derivatives include, for example, compounds discussed in U.S. Patent No. 6,514,946 that correspond in structure to Formula (I):
Figure imgf000003_0001
Here:
R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R1, R2, and R3 are each hydrogen; and
R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen.
Such compounds include, for example, 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, which has the following structure:
Figure imgf000003_0002
These compounds, and particularly 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, are believed to have pharmacokinetic and pharmacodynamic attributes for safe and effective treatment of, for example, pasteurellosis, bovine respiratory disease, and swine respiratory disease. A discussion relating to the use of these compounds to treat livestock and poultry diseases is included in U.S. Patent No. 6,514,946. That discussion is incorporated by reference into this patent.
[5] Various approaches for making macrolides have been reported. [6] In EP 0103465B1, for example, Debono et al. discuss various process steps for making compounds within their recited genus. These processes include, for example, the following reduction:
Figure imgf000004_0001
Here, R, R1, R2, R3, and R4 are defined as various substituents. R, in particular, is defined as a nitrogen-containing ring system that has up to 3 unsaturated or saturated rings that are optionally substituted. Debono et al. report that the preferred reducing agent is a cyanoborohydride, and that sodium cyanoborohydride is "the reducing agent of choice." Debono et al. also state that the solvent for this reaction will normally be an inert polar solvent, such as a Ci -C4 alkanol. See page 6, lines 7-14. In a later-filed patent in the same patent family, Debono et al. further discuss reductive amination of various aldehyde compounds (including tylosin) with an amine. Sodium cyanoborohydride and sodium boro hydride are cited as suitable reducing agents, and anhydrous methanol is cited as a suitable solvent. See U.S. Patent No. 4,820,695, col. 7, lines 60-68.
[7] In U.S. Patent No. 6,664,240, Phan et al. also discuss a reductive amination:
Figure imgf000004_0002
Here, Rp 2, R4, R7 and R8 are defined as various substituents. R7 and R8, in particular, are each defined as being independent substituents, or, alternatively, as together forming a 3- to 7-member heterocyclic ring. Phan et al. discuss conducting this reaction with a boro hydride reagent in an alcohol or acetonitrile solvent. Sodium borohydride and sodium cyanoborohydride are listed as example borohydride reagents; and methanol, ethanol, and isopropanol are listed as example alcohol solvents. See, e.g., col. 15, line 64 to col. 16, line 42; and col. 22, lines 41-49.
[8] In EP 0240264B1, Tao et al. also discuss a reductive amination:
Figure imgf000005_0001
Here, R1, R2, R3, and R4 are defined as various substituents. R3 and R4, in particular, are defined as each being independent substituents, or, alternatively, as together forming a heterocyclic ring system having up to 3 optionally substituted rings. Tao et al. report that this reduction may be achieved using formic acid as the reducing agent. Tao et al. further report that the solvent will ordinarily be an inert polar organic solvent. Amyl acetate and acetonitrile are cited as examples of such a solvent. See page 4, line 57 to page 5, line 10. See also, U.S. Patent No. 4,921,947, col. 3, line 62 to col. 4, line 16.
[9] In EP 0103465B1, Debono et al. discuss the following hydrolysis reaction:
Figure imgf000005_0002
Here, R, R1, R2, and R4 are defined as various substituents. Debono et al. report that this "hydrolysis can be effected using a strong aqueous mineral acid as hydrochloric or sulfuric acid, or a strong organic acid such as/?-toluenesulfonic acid." See page 7, lines 3-8. In a later-filed patent of the same patent family, Debono et al. further discuss mycarose
15 hydrolysis of C-20-modified derivatives of tylosin, macrocin, and DOMM using "well known" procedures for acidic hydrolysis. See U.S. Patent No. 4,820,695, Col. 8, lines 35- 43.
[10] In view of the importance of macro lides in the treatment of a plethora of pathological conditions, there continues to be a need for cost-effective, high-yield 0 processes for making macrolides. The following disclosure addresses this need.
SUMMARY OF THE INVENTION
[11] This invention relates to processes for making macrolides, and, in particular, optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof. Such processes include processes for making the macrolides themselves, as well as processes for making compounds that, inter alia, may be used as intermediates for making various macrolides.
[12] Briefly, this invention is directed, in part, to a process for making a macro lide and salts thereof. The macro lide corresponds in structure to Formula (I):
Figure imgf000006_0001
Here:
As to R R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen,
R1 and R3 are each hydrogen, and R2 is methyl, or
R1, R2, and R3 are each hydrogen. As to R4, R5, and R6:
R4 and R6 are each methyl, and R5 is hydrogen,
R4 and R6 are each hydrogen, and R5 is methyl, or
R4, R5, and R6 are each hydrogen.
[13] In some embodiments, the process comprises reacting tylosin (e.g., tylosin A or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent. In these embodiments, the piperidinyl compound of Formula (II) corresponds in structure to:
Figure imgf000006_0002
[14] In some embodiments, the process comprises reacting a 20-piperidinyl- tylosin compound with an acid. In these embodiments, the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III):
Figure imgf000007_0001
[15] In some embodiments, the process comprises reacting a 23-O-mycinosyl- 20-piperidinyl-5-O-mycaminosyl-tylonolide compound with an acid. In these embodiments, the 23 -0-mycino syl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound corresponds in structure to Formula (IV):
Figure imgf000007_0002
[16] In some embodiments, the process comprises activating a 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound with an activating agent to form an activated compound. In these embodiments, the 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound corresponds in structure to Formula (V):
Figure imgf000007_0003
(V). The activated compound (also referred to as a "23-L-20-piperidinyl-5-O-mycaminosyl- tylonolide compound") corresponds in structure to Formula (VI):
Figure imgf000008_0001
And L is a leaving group.
[17] In other embodiments, the process comprises reacting an activated compound of Formula (VI) with a piperidinyl compound of Formula (VII). In these embodiments, the piperidinyl compound of Formula (VII) corresponds in structure to:
Figure imgf000008_0002
[18] In some embodiments, the process comprises a combination of the above embodiments to make a macro lide of Formula (I) or salt thereof.
[19] In some embodiments, the process comprises one or more of the above embodiments to make, for example, an amorphous, crystalline, co-crystalline, or solvate form of the macrolide of Formula (I) or a salt thereof.
[20] This invention also is directed, in part, to a process for making the 20- piperidinyl-tylosin compound of Formula (III) or a salt thereof. In these embodiments, the process comprises reacting tylosin (e.g., tylosin A), the piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent.
[21] This invention also is directed, in part, to a process for making the 23-0- mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (IV) or a salt thereof. In these embodiments, the process comprises reacting the 20-piperidinyl- tylosin compound of Formula (III) with HBr.
[22] This invention also is directed, in part, to a process for making a 23- hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (V) or a salt thereof. In these embodiments, the process comprises reacting the 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (IV) with an acid.
[23] This invention also is directed, in part, to a process for making an activated compound of Formula (VI) or a salt thereof. In these embodiments, the process comprises activating a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound of Formula (V) with an activating agent.
[24] This invention also relates to using compounds of Formula (I) (and pharmaceutically acceptable salts thereof) prepared in accordance with this invention in methods for treating a disease, such as pasteurellosis, swine respiratory disease, or bovine respiratory disease. More specifically, this invention is directed, in part, to a method that comprises preparing a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) in accordance with one or more of the above cited methods, and then administering a therapeutically effective amount of the compound or salt to an animal in need of the treatment. This invention also is directed, in part, to using a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) prepared in accordance with this invention to prepare a medicament, particularly a medicament for use in the above treatments.
[25] Further aspects and benefits of Applicants' invention will be apparent to one skilled in the art from reading this specification.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [26] This detailed description of preferred embodiments is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This detailed description and its specific examples, while indicating preferred embodiments of this invention, are intended for purposes of illustration only. This invention, therefore, is not limited to the preferred embodiments described in this specification, and may be variously modified.
A. Macrolides That May Be Prepared By This Invention
[27] Compounds that may be prepared by the process of this invention include compounds corresponding in structure to Formula (I):
Figure imgf000010_0001
Here:
R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R1, R2, and R3 are each hydrogen; and
R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. In some embodiments, the piperidinyl substituents of Formula (I) are identical, i.e.
Figure imgf000010_0002
In some such embodiments, for example, both piperidinyl substituents are piperidine (i.e., RR11,, RR22,, RR33,, RR44,, RR55,, aanndd RR66 aarree eeaacchh hhyyddrrooggeenn), such that the compound is 20,23- dipiperidinyl-5 -0-mycamino syl-tylono lide :
Figure imgf000010_0003
Such compounds include, for example:
Figure imgf000011_0001
Other compounds having identical piperidinyl substituents include:
and
Figure imgf000011_0002
Figure imgf000011_0003
[28] In some embodiments, the piperidinyl substituents of Formula (I) are not identical, i.e. :
IS DIFFERENT THAN
Figure imgf000011_0005
Figure imgf000011_0004
Compounds having different piperidinyl substituents include:
Figure imgf000011_0006
Figure imgf000012_0001
B. Macrolide Synthesis
[29] This invention may be used to synthesize macro lides from materials generally available in the art.
B-I. Preparation of 20-Piperidinyl-Tylosin Compound [30] In some embodiments, the macrolide synthesis begins by or includes preparing a 20-piperidinyl-tylosin compound, and particularly a compound corresponding in structure to Formula (III):
Figure imgf000012_0002
In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen, such that the compound corresponds in structure to:
Figure imgf000013_0001
[31] The 20-piperidinyl-tylosin compound may be prepared from tylosin A and a piperidinyl compound via a reductive amination reaction using a reducing agent comprising formic acid (or "HCOOH"):
Figure imgf000013_0002
piperidinyl tylosin A reagent
formic acid
Figure imgf000013_0003
20-piperidinyl-tylosin compound
Where R . 1 , r R> 2 , and R are each hydrogen, this reaction is as follows:
Figure imgf000014_0001
formic acid
Figure imgf000014_0002
Tylosin A, piperidinyl compounds, and formic acid are commercially available.
[32] The tylosin A reagent may, for example, be pure (or at least essentially pure) tylosin A. Alternatively, as noted below in Section B-7, the tylosin A reagent may be part of a mixture, such as, for example, a mixture comprising tylosin A as well as one or more tylosin A derivatives, such as tylosin B, tylosin C, and/or tylosin D.
[33] The tylosin A may be in the form of its free base, or, alternatively, in the form of a salt. The tylosin A derivatives likewise are optionally in the form of one or more salts. It is contemplated that a variety of salts may be suitable. In some embodiments, for example, the salt comprises a phosphate salt. In other embodiments, the salt comprises a tartrate salt. In still other embodiments, the salt comprises a citrate or sulfate salt. Further discussion relating to salts may be found below in Section C.
[34] The solvent may comprise one or more solvents. Although the solvent may comprise one or more polar solvents in some embodiments, the solvent preferably instead comprises one or more non-polar solvents. A "non-polar solvent" is a solvent that does not ionize sufficiently to be electrically conductive, and cannot (or at least essentially cannot) dissolve polar compounds (e.g., various inorganic salts), but can dissolve nonpolar compounds (e.g., hydrocarbons and resins). In general, the solvent preferably is non- reactive with the reagents, products, and any other ingredients in the reaction mixture. The solvent may comprise, for example, chloroform (or "CHCI3"); tetrahydrofuran (or "THF"); dichloromethane (or "CH2Cl2" or "DCM" or "methylene chloride"); carbon tetrachloride (or "CCl4"); ethyl acetate (or "CH3COOC2H5"); diethyl ether (or "CH3CH2OCH2CH3"); cyclohexane (or "C6Hi2"); or aromatic hydrocarbon solvents, such as benzene (or "C6H6"), toluene (or "C6H5CH3"), xylene (or "C6H4(CHs)2" or "dimethylbenzene" (including 1,3- dimethylbenzene (or "m-xylene"), 1 ,2-dimethylbenzene (or "o-xylene"), or 1,4- dimethylbenzene (or "/^-xylene")), ethylbenzene, or mixtures thereof (e.g., mixtures of m- xylene, o-xylene, /^-xylene, and/or ethylbenzene). In some embodiments, the solvent comprises dichloromethane, chloroform, or ethyl acetate. In other embodiments, the solvent comprises xylene. In still other embodiments, the solvent comprises toluene. In some such embodiments, toluene is particularly preferred because of its ease of use at typical reaction temperatures. [35] In some embodiments, the solvent comprises a mixture of solvents. In some such embodiments, for example, the solvent comprises a mixture of toluene and DCM. Here, the toluene/DCM ratio may be, for example, from about 1 :1 to about 100:1, or from about 5:1 to about 8:1 (v/v). In some of these embodiments, the ratio is, for example, about 8:1 (v/v). In others, the ratio is, for example, about 5.3:1 (v/v). [36] To perform the amination, the tylosin A reagent, piperidinyl compound, formic acid (or a source of formic acid), and solvent normally are charged to a reactor and mixed. These ingredients may generally be charged to the reactor in any sequence.
[37] The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the reaction mixture may be used. For example, stainless steel reactors generally may be used as well.
[38] Typically, equimolar amounts of the tylosin A reagent, piperidinyl compound, and formic acid may be used. Normally, however, excess amounts of the piperidinyl compound and formic acid are used, relative to the molar amount of tylosin A reagent.
[39] In some embodiments, from 1 to about 3 equivalents (or from 1.05 to about 3 equivalents) of the piperidinyl compound are charged to the reactor. In some such embodiments, for example, from 1.05 to about 1.2 equivalents of piperidinyl compound are charged to the reactor. In other such embodiments, from about 1.07 to about 1.5 equivalents of piperidinyl compound are charged to the reactor. Here, for example, about 1.3 equivalents of the piperidinyl compound may be charged to the reactor. In some embodiments, the piperidinyl compound is charged to the reactor in two or more separate charges over time, preferably with the subsequent charge(s) being less than the first charge. In some embodiments, for example, the piperidinyl compound is charged to the reactor in two charges, with the amount of the second charge being about 10% of the first charge. Applicants have discovered that this can be beneficial for increasing conversion.
[40] In some embodiments, from 1 to about 10 equivalents (or from 1.05 to about 10 equivalents, from about 2 to about 5 equivalents, or from about 2.5 to about 4.5 equivalents) of formic acid are used. In some such embodiments, for example, about 4.5 equivalents of formic acid are used. In other such embodiments, from about 2.5 to about 4 equivalents of formic acid are used. For example, in some such embodiments, about 3.0 equivalents of formic acid are used.
[41] Typically, the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents. In some embodiments, the amount of solvent is at least about 1 L per kg tylosin A reagent (or, where the tylosin A reagent is part of a mixture of tylosin A reagent and derivates thereof, per kg of the total tylosin mixture). The amount of solvent generally is less than about 40 L per kg tylosin A reagent (or tylosin mixture). In some embodiments, the amount of solvent is from about 2 to about 15 L (or from about 5 to about 15 L, from about 5 to about 12 L, from about 5 to about 10 L, or from about 8 to about 10 L) per kg tylosin A reagent (or tylosin mixture). To illustrate, in some such embodiments, the solvent comprises toluene or a mixture of toluene and DCM, and the amount of solvent is from about 8 to about 10 L per kg tylosin A reagent (or tylosin mixture). Here, for example, the amount of solvent may be about 8 L per kg tylosin A reagent (or tylosin mixture).
[42] At least a portion of the reaction (or the entire reaction) is typically conducted at greater than about 2O0C, greater than about 250C, or greater than about 6O0C. In general, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and, more typically, is less than the boiling point. When, for example, the solvent is toluene, at least a portion of the reaction (or the entire reaction) is typically conducted at less than about HO0C. Illustrating further, when the solvent is xylene, at least a portion of the reaction (or the entire reaction) is normally conducted at less than about 1650C. In general, at least a portion of the reaction (or the entire reaction) is conducted at from about 60 to about 950C, from about 70 to about 850C, from about 70 to about 8O0C, or from about 75 to about 8O0C. In some embodiments, for example, the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 8O0C. In other embodiments, for example, the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 760C. Although lesser temperatures than the above ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than the above ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.
[43] This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure. In preferred embodiments, this reaction is conducted under an inert atmosphere (e.g., N2).
[44] The reaction time may depend on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, typically at least about 5 minutes, and more typically at least about 1 hour. The reaction time is generally less than about 24 hours. In some embodiments, for example, the reaction time is from about 0.5 to about 12 hours, or from about 1 to about 4 hours. In some such embodiments, the reaction time is about 3.5 hours. In other such embodiments, the reaction time is from about 1 to about 3 hours. In these embodiments, the reaction time may be, for example, about 2 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
[45] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
B-2. Preparation of23-O-Mycinosyl-20-Piperidinyl-5-O-Mycaminosyl-Tylonolide
Compound
(Hydrolysis of Mycarosyloxy Substituent)
[46] In some embodiments, the macrolide synthesis begins by or includes preparing a 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure to Formula (IV):
Figure imgf000018_0001
In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen such that the compound corresponds in structure to:
Figure imgf000018_0002
[47] The IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound may be prepared via acid hydrolysis of a 20-piperidinyl-tylosin compound:
Figure imgf000019_0001
20-piperidinyl-tylosin compound
Figure imgf000019_0002
IS-O-mycinosyHO-piperidinyl-S-O-mycaminosyl-tylonolide compound
When R1, R2, and R3 are each hydrogen, this reaction is as follows:
Figure imgf000019_0003
acid
Figure imgf000019_0004
[48] The 20-piperidinyl-tylosin compound used in the above reaction may be prepared using a process discussed above in Section B-I, prepared using a different process (e.g. , a process using a borohydride as a reducing agent), or obtained from a commercial vendor. In some preferred embodiments, the 20-piperidinyl-tylosin compound is prepared using a process discussed above in Section B-I.
[49] The acid may, for example, be a strong mineral acid, such as hydrochloric acid (or "HCl"), nitric acid (or "HNO3"), fluoroboric acid (or "HBF4"), sulfuric acid (or "H2SO4"), phosphoric acid (or "H3PO4"), polyphosphonic acid (or "PPA"), or hydrobromic acid (or "HBr"); or a strong organic acid, such as/?-toluenesulfonic acid or trifluoroacetic acid ("CF3COOH"). In some embodiments, the acid comprises HCl. In other embodiments, the acid comprises HBr. Use of HBr tends to coincide with a less amount of impurities in the product mixture relative to the product obtained using, for example, HCl. In some embodiments, a mixture of acids (particularly a strong acid with another acid) is used.
[50] In general, sufficient acid is mixed with the 20-piperidinyl-tylosin compound to hydro lyze (i.e., cleave) the mycarosyloxy substituent to form a hydroxyl group. Typically, the amount of acid will be at least about one equivalent, based on the amount of 20-piperidinyl-tylosin compound. In general, the acid is added to the reaction mixture in the form of a concentrated composition. The concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30% (mass/vol), or from about 1 to about 24% (mass/vol). In some embodiments, for example, the acid is HBr, and the concentration of the acid solution added to the reaction mixture is about 24% (mass/vol). In some embodiments, the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.
[51] The ingredients may generally be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the acidic reaction mixture may be used.
[52] At least a portion of the hydrolysis (or the entire hydrolysis) normally is conducted at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous. A temperature of at least about 1O0C (or greater than about 150C, or greater than about 250C) is typically preferred. In general, the reaction temperature is not greater than the boiling point of the solvent (e.g., water), and typically is less than the boiling point. In some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 1000C (or not greater than about 650C). In some embodiments where the acid is HCl or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 20 to about 6O0C. In some such embodiments, the reaction temperature over at least a portion of the reaction (or the entire reaction) is not greater than about 4O0C. In such instances, the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, from about 20 to about 4O0C, from about 25 to about 4O0C, or from about 30 to about 4O0C. In other embodiments where the acid is HCl or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 45 to about 6O0C, or from about 50 to about 560C. To illustrate, in such embodiments, the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, about 560C. Although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. And, although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. Such rates, however, may still be suitable, given the ease with which this hydrolysis occurs. [53] The reaction mixture may be maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In such embodiments, the temperature tends to increase once the acid has been charged to the reactor.
[54] This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
[55] The reaction time will depend on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time may be less than a minute, essentially spontaneous, or spontaneous. Generally, however, the reaction time is at least about 1 minute, more typically at least about 5 minutes, and still more typically at least about 15 minutes. Normally, the reaction time is less than about 3 hours. In some embodiments, for example, the reaction time is from about 0.25 to about 2 hours, from about 0.25 to about 1.5 hours, or from about 0.25 to about 1.1 hours. Although lesser reaction times may be used, such reaction times may coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower. [56] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
B- 3. Preparation of23-Hydroxyl-20-Piperidinyl-5-O-Mycaniinosyl-Tylonolide Compound
(Hydrolysis of Mycinosyloxy Substituent)
[57] In some embodiments, the macrolide synthesis begins by or includes preparing a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure for Formula (V):
Figure imgf000022_0001
In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen:
Figure imgf000022_0002
[58] The 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound may be prepared via an acid hydrolysis reaction from a 23-O-mycinosyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound:
Figure imgf000023_0001
23-O-mycinosyl-20-piperidinyl- 23-hydroxy-20-piperidinyl- 5-O-mycaminosyl-tylonodide compound 5-O-mycaminosyl-tylonodide compound
Where R , 1 , r R> 2 , and R are each hydrogen, this reaction is as follows:
Figure imgf000023_0002
[59] The IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound used in the above reaction may be prepared using a process discussed above in Section B-2, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound is prepared using a process discussed above in Section B-2.
[60] The acid may, for example, be a strong mineral acid, such as hydrochloric acid, nitric acid, fluoroboric acid, sulfuric acid, phosphoric acid, polyphosphonic acid, or hydrobromic acid; or a strong organic acid, such as/?-toluenesulfonic acid or trifluoroacetic acid. In some embodiments, the acid comprises HCl. In some preferred embodiments, the acid comprises HBr. As with the hydrolysis discussed above in Section B-2, this preference stems from the tendency of HBr to coincide with a less amount of impurities in the product mixture relative to, for example, HCl. In some embodiments, a mixture of acids (particularly a mixture of a strong acid with another acid) is used.
[61] In embodiments where the mycinosyloxy hydrolysis occurs after the acid hydrolysis of mycarosyloxy discussed above in Section B-2, the acids used in the mycinosyloxy and mycarosyloxy hydrolysis reactions may be different, although it is generally more preferred for the acids to be the same. In some embodiments, for example, HCl is used in both reactions. In other embodiments, HBr is used in both reactions. [62] In general, sufficient acid is mixed with the 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound to hydro lyze the mycinosyloxy substituent to form a hydro xyl group. Typically, the amount of acid will be greater than about one equivalent, based on the molar amount of 23-O-mycinosyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound. In general, the acid is added to the reaction mixture in the form of a concentrated composition. The concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30% (mass/vol), or from about 1 to about 24% (mass/vol). In some embodiments, for example, the acid is HBr, and concentration of the acid solution added to the reaction mixture is about 24% (mass/vol). In some embodiments, the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.
[63] The ingredients may generally be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, although any composition stable when exposed to the acidic reaction mixture may be used. [64] The mixture normally is maintained at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous. The reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is not greater than the boiling point of the solvent (e.g., water), and typically is less than the boiling point. In general, at least a portion of the reaction (or the entire reaction) is conducted at a temperature of at least about 1O0C, greater than about 250C, or at least about 480C. The reaction temperature over at least a portion of the reaction (or the entire reaction) typically is not greater than about 1000C, or not greater than about 650C. In some embodiments, for example, the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 10 to about 1000C. In some embodiments when the acid is HCl or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is from about 48 to about 6O0C. In some such embodiments, for example, the temperature over at least a portion of the reaction (or the entire reaction) is from about 55 to about 6O0C. In other such embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 51 to about 570C (e.g., about 540C). In still other such embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 50 to about 560C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.
[65] As with the mycarosyloxy hydrolysis discussed above in Section B-2, the mycinosyloxy hydrolysis reaction mixture may be maintained at a temperature that is slightly less than the desired reaction temperature while at least a portion of the acid (or all the acid) is being charged to the reactor.
[66] This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
[67] The reaction time depends on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, and more typically at least about 15 minutes. Typically, the reaction time is less than about 7 hours. In some embodiments, for example, the reaction time is from about 0.5 to about 7 hours. In some such embodiments, for example, the reaction time is from about 1 to about 5 hours, or from about 3 to about 5 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
[68] When the mycinosyloxy hydrolysis occurs after the mycarosyloxy hydrolysis discussed above in Section B-2, the two reactions (i.e., those described above in Section B-2 and this Section B-3) may be carried out as two discrete steps or as a single reaction. When the reactions are carried out as a single reaction, the reaction mixture may be maintained at the same temperature or changed (typically increased) over time. If the reaction mixture is maintained at the same temperature, the mixture normally is maintained at a temperature of at least about 1O0C, typically greater than about 250C, more typically at least about 3O0C, and still more typically at least about 450C. In some embodiments, the temperature is maintained at from about 10 to about 1000C. In some such embodiments, for example, the temperature is from about 48 to about 7O0C. In other such embodiments, for example, the temperature is from about 50 to about 560C. In other such embodiments, for example, the temperature is from about 55 to about 6O0C. In still other such embodiments, the temperature is from about 65 to about 7O0C. If the temperature of the mixture is increased over time, the temperature of the mixture at the beginning of the hydrolysis normally is at least about 150C, or at least about 250C. As the reaction progresses from the mycarosyloxy hydrolysis to the mycinosyloxy hydrolysis, the temperature preferably is increased to at least about 3O0C, at least about 450C, or from about 48 to about 7O0C. In some such embodiments, the increased temperature is from about 50 to about 560C. In other such embodiments, the increased temperature is from about 55 to about 6O0C. In still other such embodiments, the increased temperature is from about 65 to about 7O0C. In some embodiments, the reaction mixture is maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In those embodiments, the temperature tends to increase once the acid has been charged to the reactor.
[69] The total reaction time when the two hydrolysis reactions are combined depends on various factors including, for example, reaction temperature, relative amounts of the ingredients, and the desired conversion. Generally, however, the reaction time for the combined hydrolysis reactions in a batch reactor is at least about 4 hours. In some embodiments, the combined reaction time is from about 4 to about 6 hours. In some such embodiments, for example, the combined reaction time is about 4 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is from about 65 to about 7O0C. In other embodiments, the reaction time is about 5 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is from about 55 to about 6O0C.
[70] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.
B-4. Preparation of the Activated Compound
[71] In some embodiments, the macrolide synthesis begins by or includes preparing an activated compound, and particularly a compound that corresponds in structure to Formula (VI):
Figure imgf000027_0001
[72] In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen, such that the compound corresponds in structure to:
Figure imgf000027_0002
[73] L is a leaving group. In general, the leaving group is a group that may be replaced with a piperidinyl group (normally via nucleophilic displacement) using piperidine in an amination reaction, such as the amination reaction discussed below in Section B-5. In some embodiments, for example, L is iodo (-1), bromo (-Br), alkylsulfonate, and arylsulfonate. The alkylsulfonate and arylsulfonate are optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, and haloalkyl. In some such embodiments, for example, L is iodo, bromo, methylsulfonate (or "-OS(O)2CHs" or "mesylate"), trifluoromethylsulfonate (or "-OS(O)2CF3" or "trifiate"), or 4-methylphenylsulfonate (or >-toluenesulfonate" or "tosylate"). In some embodiments, L is iodo, and the activated compound corresponds in structure to:
Figure imgf000028_0001
or, when R1, R2, and R3 are each hydrogen, corresponds in structure to:
Figure imgf000028_0002
In some embodiments, L is mesylate, and the activated compound corresponds in structure to:
Figure imgf000028_0003
or, when R1, R2, and R3 each are hydrogen, corresponds in structure to:
Figure imgf000028_0004
In some embodiments, L is tosylate, and the activated compound corresponds in structure to:
Figure imgf000029_0001
or, when R1, R2, and R3 each are hydrogen, corresponds in structure to:
Figure imgf000029_0002
In some embodiments, L is triflate, and the activated compound corresponds in structure to:
Figure imgf000029_0003
or, when R1, R2, and R3 each are hydrogen, corresponds in structure to:
Figure imgf000029_0004
[74] The activated compound may be prepared via an activation reaction from a IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound and an activating agent (i.e., a compound comprising an electron withdrawing group):
Figure imgf000030_0001
23-hydroxyl-20-piperidinyl- activated compound 5-O-mycaminosyl-tylonolide compound
Where R , 1 , r R> 2 , and R are each hydrogen, this reaction is as follows:
Figure imgf000030_0002
[75] The IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound used in the above reaction may be prepared using a process discussed above in Section B- 3, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound is prepared using a process discussed above in Section B-3.
[76] In some embodiments, L is iodo, and the activating agent is formed by mixing I2 and triphenylphosphine:
Figure imgf000030_0003
[77] Typically, this reaction is conducted in the presence of one or more solvents. In general, the solvent is non-reactive with the reagents, products, and any other ingredients in the reaction mixture (although, as noted below, the solvent may, for example, act as a helping base). The solvent may be, for example, one or more of dichloromethane ("DCM"), acetone, acetonitrile ("ACN"), tert-butyl methyl ether (or "tBME"), toluene, and pyridine. In some embodiments, for example, the solvent comprises tetrahydrofuran ("THF"). In other embodiments, the solvent comprises pyridine, which also may act as a helping base. In still other embodiments, the solvent comprises dichloromethane. In some such embodiments, for example, the solvent comprises both dichloromethane and toluene. In some embodiments, the ratio of dichloromethane to toluene is, for example, be at least about 1 :1, from about 3:1 to about 10 : 1 , or from about 3 : 1 to about 5:1. In some embodiments, at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. [78] In general, the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, dissolve the reagents (particularly the 23-hydroxyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound), and promote homogenous distribution of the reagents. The amount of solvent typically is at least about 1 L per kilogram of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. The amount of solvent typically is not greater than about 100 L per kilogram of the 23- hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. In some embodiments, the amount of solvent is from about 5 to about 20 L (or from about 5 to about 15 L, or from about 10 to about 12 L) per kilogram of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound. To illustrate, in some embodiments, the amount of solvent is about 10 L DCM per kilogram. In other embodiments, the amount of solvent is about 12 L DCM per kilogram. In still other embodiments, the solvent is a mixture of DCM and toluene (about 4:1 vol/vol), and the amount of solvent is about 10 L per kilogram.
[79] As indicated above, this reaction may be conducted in the presence of a base (or "helping base"). The base may be a single base, or a combination of bases. This base may comprise, for example, triethylamine, pyridine, imidazole, potassium carbonate, and/or 4-dimethylaminopyridine (or "DMAP"). The presence of the base may increase the reaction rate. In some embodiments, the base comprises pyridine. In some such embodiments, for example, the activating agent comprises I2 and triphenylphosphine. In other embodiments, the base comprises imidazole. In other embodiments, the base comprises a combination of potassium carbonate and 4-dimethylaminopyridine. In some such embodiments, for example, the activating agent comprises /?-toluenesulfonyl chloride. In some embodiments, the helping base is attached to a solid support (e.g., a resin). [80] When a base is used, the molar amount of the base is typically at least equivalent to the molar amount of IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound. In some embodiments, the amount of the base is at least 1.05 equivalents. For example, in some embodiments, the molar amount of the base is from about 1.1 to about 10 equivalents, from about 1.1 to about 5 equivalents, or from about 1.1 to about 3 equivalents. In some such embodiments, the molar amount of base is from about 1.1 to about 1.4 equivalents (e.g., about 1.15 or about 1.3 equivalents). In other such embodiments, the molar amount of the base is about 2.8 equivalents. When a combination of bases is used, the total molar amount of base preferably falls within the ranges described above. For example, when the source of the activating agent comprises /?-toluenesulfonyl chloride, an example of a contemplated amount of base is about 1.5 equivalents of potassium carbonate and about 1.0 equivalents of 4-dimethylaminopyridine, based on the amount of the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. [81] When the source of the activating agent is I2 and triphenylphosphine, the I2, triphenylphosphine, and base (if present) are typically first combined in the presence of solvent to form the activating agent before they are combined with the 23-hydroxyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound. The reactor in which the activating agent is formed may be the same reactor in which the activating agent is combined with the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. Alternatively, the activating agent may be formed in a different reactor, and then charged to the reactor to which the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound is charged. The I2 may be added in one or more doses to the triphenylphosphine or vice versa. In some embodiments, the I2 is added to the triphenylphosphine in two or more portions (e.g., 5 portions) or vice versa. The portions may be equal or different amounts. Generally, the combination of the I2 and triphenylphosphine takes place in the presence of a solvent, which may, for example, comprise the solvent(s) that is used in the substitution reaction. If a base (e.g., pyridine) is present, it is typically combined with the triphenylphosphine before the I2 is added. The mixture preferably is maintained at from about 15 to about 350C (or from about 20 to about 3O0C, e.g., about 250C) during the addition of I2 to the triphenylphosphine, and then maintained at a temperature of from about 15 to about 350C (or from about 20 to about 3O0C, e.g., about 250C) after the addition for at least about one minute (e.g., about 2 minutes), or for at least about 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., about 40 minutes). Afterward, the temperature preferably is adjusted to a temperature that is approximately equal to the temperature at which the substitution reaction is to be initiated.
[82] To perform the substitution reaction, equimolar amounts of the 23- hydroxyl^O-piperidinyl-S-O-mycaminosyl-tylonolide compound and activating agent generally may be used. Normally, however, an excess of the activating agent is used, and typically at least 1.05 equivalents are used, based on the molar amount of 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound.
[83] In some embodiments when the activating agent is formed from I2 and triphenylphosphine, the molar amounts of I2 and triphenylphosphine are each at least 1.05 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound. For example, in some such embodiments, the molar amounts of I2 and triphenylphosphine are each from 1.05 to about 10 equivalents, from 1.05 to about 5 equivalents, or from 1.05 to about 3 equivalents. Although the equivalents of each of I2 and triphenylphosphine may be the same, the equivalents of triphenylphosphine typically exceeds the equivalents of I2. To illustrate, suitable molar amounts of I2 and triphenylphosphine may be about 2.5 and 2.6 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. In other embodiments, suitable molar amounts of I2 and triphenylphosphine are about 1.9 and 2.0 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound. In still other embodiments, a suitable molar amount of I2 is from 1.05 to about 1.2 equivalents, based on the molar amount of 23-hydroxyl-20- piperidinyl-5-O-mycamino syl-tylono lide compound; and a suitable amount of triphenylphosphine is from about 1.09 to about 1.25 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound. For example, suitable molar amounts of I2 and triphenylphosphine may be about 1.06 and about 1.13 equivalents, respectively, based on the molar amount of 23-hydroxyl-20- piperidinyl-5-O-mycamino syl-tylono lide compound. Exemplifying further, suitable molar amounts of I2 and triphenylphosphine may alternatively be about 1.2 and about 1.25 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
[84] In some embodiments when the activating agent is /?-toluenesulfonyl chloride, the molar amount ofp-toluenesulfonyl chloride is from about 1.1 to about 10 equivalents, from about 1.2 to about 5 equivalents, or from about 1.2 to about 3 equivalents, based on the molar amount of IS-hydroxyl-lO-piperidinyl-S-O-mycaminosyl- tylonolide compound. A suitable molar amount of /?-toluenesulfonyl chloride may be, for example, 1.2 equivalents.
[85] The substitution reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
[86] The reaction temperature for at least a portion of the substitution reaction (or the entire substitution reaction) typically is greater than the freezing point of the solvent. In general, the reaction temperature over at least a portion of the substitution (or the entire substitution) is not greater than the boiling point of the solvent, and typically is less than the boiling point. In some embodiments, for example, the solvent is dichloromethane, and at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 450C. In some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 320C, or not greater than about 250C. In some such embodiments, for example, at least a portion of the reaction (or the entire reaction) is conducted at from about -1O0C to about 250C. For example, in some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about zero to about 2O0C, or from about 12 to about 180C (e.g., about 130C). In other embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about -1O0C to about 450C, or from about 25 to about 450C. In still other embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about -10 to about O0C, or from about -6 to about -50C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. Use of some sources of the activating agent (e.g., toluenesulfonyl chloride), however, may allow for greater temperatures to be used (e.g., from about 25 to about 450C). When the activating agent is iodine, it is typically preferred to conduct the substitution reaction within a temperature range that does not produce an unacceptable level of impurities resulting from di-iodination of the 23-hydroxyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound.
[87] The reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the total reaction time is typically at least about 1 minute, and more typically at least about 45 minutes. In general, the total reaction time is less than about 24 hours. In some embodiments, for example, the total reaction time is less than about 5 hours. To illustrate, in some embodiments, the reaction time is from about 45 minutes to about 5 hours, or from about 1 to about 3 hours. In some such embodiments, for example, the reaction time is from about 2 to about 3 hours, or from about 2 to about 2.5 hours (e.g., about 2 or about 2.2 hours). In other embodiments, the reaction time is from about 5 to about 10 hours, from about 6 to about 10 hours, from about 7 to about 10 hours, or from about 7 to about 8 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.
[88] Due to the exothermic nature of the substitution reaction, in some embodiments (particularly those using a batch reactor), the 23-hydroxyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound is combined with the activating agent over time (or in multiple separate doses) rather than all at once. In some embodiments, this occurs over a period of at least one minute, at least 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., about 50 minutes). To illustrate, in some embodiments, the substitution reaction is conducted at a maximum temperature of about 250C, and the dosing of the activating agent occurs over from about 0.5 to about 1 hour, followed by an additional reaction time of about 1 hour. In other embodiments, the substitution reaction is conducted at a maximum temperature of about -50C, and the dosing of the activating agent occurs over from about 0.7 to about 1 hour, followed by an additional reaction time of about 7 hours.
[89] In some embodiments, the substitution reaction is quenched to inactivate any residual iodine, and, therefore, reduce (and preferably prevent) by-product formation due to such residual iodine. For example, in some such embodiments, the reaction is quenched with aqueous sodium sulfite (i.e., Na2SOs). Purification or isolation of the product may be achieved using, for example, various methods known in the art.
Alternatively, the product may be used in the next step without further purification or isolation.
[90] Both the activating agent formation reaction and the substitution reaction may be conducted in various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. The reactor may be made of any composition that remains stable when exposed to the reaction mixture. Such materials include, for example, various materials, such as glass (including glass-lining) or stainless steel.
B-5. Preparation of the Macrolide
[91] As noted above, the macro lides prepared in accordance with this invention correspond in structure to Formula (I):
Figure imgf000036_0001
Here:
As to R R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R1, R2, and R3 are each hydrogen.
As to R4, R5, and R6:
R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. In some embodiments, R1, R2, R3, R4, R5, and R6 are each hydrogen:
Figure imgf000036_0002
(I-A). In some such embodiments, for example, the compound corresponds in structure to the following formula:
Figure imgf000037_0001
[92] In some embodiments, the preparation of the macro lide begins by or includes an amination reaction of an activated compound with a piperidinyl compound:
Figure imgf000037_0002
activated piperidinyl macrolide compound reagent
Where R1, R2, R3, R4, R5, and R6 are each hydrogen, this reaction is as follows:
Figure imgf000037_0003
[93] The activated compound used in the above reaction may be prepared using a process discussed above in Section B-4, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the activated compound is prepared using a process discussed above in Section B-4.
[94] Typically, this reaction is conducted in the presence of one or more solvents. In general, the solvent is non-reactive with the reagents (e.g., the activated compound), products, and any other ingredients in the reaction mixture. The solvent may be, for example, acetonitrile (or "CH3CN"); chloroform; dichloromethane; tetrahydrofuran; a ketone solvent, such as acetone (or "CH3COCH3"); a hydrocarbon solvent, such as an aromatic hydrocarbon solvent (e.g., toluene or xylene); or a base, such as pyridine or piperidine. In some embodiments, the solvent comprises acetonitrile. In some embodiments, the solvent comprises tetrahydrofuran. In some embodiments, the solvent comprises dichloromethane. In some embodiments, the solvent comprises xylene. In some embodiments, at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the activated compound.
[95] The amount of solvent can vary widely, from no solvent at all to amounts that create diluted reaction mixtures. Typically, the amount of solvent is sufficient to, for example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents. In some embodiments, sufficient solvent is present such that the combined amount of activating reagent and macro lide is from about 5 to about 50% (mass/volume) of the reaction mixture. In some embodiments, the amount of solvent is at least about 1 L per kilogram activated compound. In some such embodiments, for example, the amount of solvent is from about 1 to about 100 L (or from about 1 to about 20 L) per kilogram of activated compound. To illustrate, in some embodiments, about 5 L of solvent (e.g., xylene or tetrahydrofuran) are used per kilogram of activated compound. Illustrating further, in other embodiments, about 10 L of solvent (e.g., acetonitrile) are used per kilogram of activated compound.
[96] In some embodiments, the amination is conducted in the presence of a base. In some embodiments, the base comprises an un-hydrated base. The base may be, for example, potassium carbonate (or "K2CO3"), sodium carbonate (or "Na2COs"), or a tertiary amine. The presence of such a base tends to coincide with a greater reaction rate and less production of impurities. It is believed that such advantages may stem from the base deprotonating protonated piperidinyl compound. The base preferably is not so strong as to cause hydrolysis of the lactone in the macro lide core. Generally, equimolar amounts of the activated compound and base may be used. Normally, however, an excess of base is used. In some embodiments, at least 1.05 (or from about 1.1 to about 50, from about 2 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of base are used, based on the molar amount of activated compound charged to the reactor. In some such embodiments, about 6.2 equivalents of base are used. In other some such embodiments, about 10 equivalents of base are used. In still other such embodiments, from about 1.1 to about 10 (or from about 2 to about 8, or from about 4 to about 6) equivalents of base are used, based on the molar amount of activated compound charged to the reactor. To illustrate, a suitable amount of base may be, for example, about 5 equivalents.
[97] To perform the amination, the activated compound, piperidinyl compound, and solvent, as well as any base (to the extent present), are normally charged to a reactor and mixed. These ingredients generally may be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass, glass-lined, and stainless steel reactors are often preferred, although any composition stable when exposed to the reaction mixture may be used.
[98] Generally, equimolar amounts of the activated compound and piperidinyl compound may be used. Normally, however, an excess of the piperidinyl compound is used. In some embodiments, at least 1.05 (or from about 1.1 to about 50, from about 2 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of the piperidinyl compound are used, based on the molar amount of activated compound charged to the reactor. In some such embodiments, about 10 equivalents of the piperidinyl compound are used. In other such embodiments, from about 2 to about 8 (or from about 4 to about 6) equivalents are used, based on the molar amount of activated compound charged to the reactor. To illustrate, a suitable amount of piperidinyl compound may be, for example, about 4.7 equivalents. A contemplated suitable amount of piperidinyl compound also may be, for example, about 5.7-5.8 equivalents.
[99] At least a portion of the reaction (or the entire reaction) normally is conducted at greater than about 2O0C, or greater than about 250C. The optimal reaction temperature depends on, for example, the solvent. Typically, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and typically is less than the boiling point. In general, at least a portion of the reaction (or the entire reaction) is conducted at from about 50 to about HO0C. In some embodiments, for example, at least a portion of the reaction (or the entire reaction) is conducted at from about 60 to about HO0C, or from about 75 to about HO0C. To illustrate, when the solvent comprises acetonitrile or toluene, a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 780C to about HO0C (e.g., about 780C). To illustrate further, when the solvent comprises xylene, a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 95 to about 1050C, and a suitable reaction time for the reaction is about 15 hours. In other embodiments, the solvent comprises tetrahydrofuran, and at least a portion of the reaction (or the entire reaction) is conducted at from about 55 to about 750C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. Typically, lesser temperatures may be used with solvents having greater polarities. The temperature can be adapted accordingly by one skilled in the art.
[100] In some embodiments, the amination reaction is conducted at more than one temperature. For example, the reaction may be conducted at one temperature initially, and then slowly increased to another temperature as the reaction progresses.
[101] The amination may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.
[102] The reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, at least about 5 minutes, or at least about 45 minutes. The reaction time is generally no greater than about 24 hours. In some embodiments, the reaction time is from about 2 to about 15 hours. In other embodiments, the reaction time is from about 1 to about 5 hours, from about 2 to about 4 hours, or from about 2 to about 3 hours (e.g., about 2.5 hours). In other such embodiments, the reaction time is from about 6 to about 15 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions.
[103] Further purification or isolation of the product may be achieved using, for example, various methods known in the art. B-6. Examples of Contemplated Reaction Schemes
[104] This invention contemplates any processes that use any of the above reactions. In some embodiments, the process will comprise one of the above reactions. In other embodiments, the process will comprise two, three, four, or all the above reactions. The following Scheme I generically illustrates a scenario where all the above reactions are used:
Scheme I
Figure imgf000041_0001
Here:
As to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen;
R1 and R3 are each hydrogen, and R2 is methyl; or
R1, R2, and R3 are each hydrogen. As to R4, R5, and R6:
R4 and R6 are each methyl, and R5 is hydrogen;
R4 and R6 are each hydrogen, and R5 is methyl; or
R4, R5, and R6 are each hydrogen. L is a leaving group. [105] The following Scheme II generically illustrates the above scenario where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the source of the activating agent comprises I2, triphenylphosphine, and pyridine; and the final amination reaction mixture comprises potassium carbonate:
Scheme II
Figure imgf000042_0001
[106] The following Scheme III generically illustrates the scenario of Scheme I where the two hydrolysis reactions are conducted without stopping the first hydrolysis or isolating product from the first hydrolysis before conducting the second hydrolysis:
Scheme III
"OH
Figure imgf000043_0001
[107] The following Scheme IV generically illustrates the scenario of Scheme I where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the first hydrolysis is not stopped and the product of the first hydrolysis is not isolated before conducting the second hydrolysis; the source of the activating agent comprises I2, triphenylphosphine, and pyridine; and the final amination reaction mixture comprises potassium carbonate:
Scheme IV
Figure imgf000044_0001
[108] The following Scheme V generically illustrates a 2-stage scenario of Scheme I where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the reductive amination and first hydrolysis are not stopped and the products of the reductive amination and first hydrolysis are not isolated before conducting the second hydrolysis; the source of the activating agent comprises I2, triphenylphosphine, and pyridine; the final amination reaction mixture comprises potassium carbonate; and the activation reaction is not stopped and the product of the activation reaction is not isolated before conducting the final amination reaction:
Scheme V
Figure imgf000045_0001
B-7. Tylosin Reagent
[109] In general, the tylosin reagent used in the processes of this invention comprises tylosin A (or a salt thereof):
Figure imgf000045_0002
Tylosin A. Although this invention contemplates the use of pure (or at least essentially pure) tylosin A (or a salt thereof), various commercially available tylosin compositions additionally or alternatively may comprise one or more derivatives of tylosin A, including:
Figure imgf000046_0001
tylosin B (also known as desmycocin),
Figure imgf000046_0002
tylosin C (also known as macrocin), and
Figure imgf000046_0003
tylosin D (also known as relomycin). In general, these derivatives, if present, are present in only small amounts. In some embodiments, the weight ratio of tylosin A to the total combined amount of tylosin A derivatives in the composition is at least about 1 :1. In some such embodiments, for example, the ratio is at least about 4:1, at least about 10:1, at least about 95:5, at least about 98:2, or at least about 99:1. In other such embodiments, about 100% (by weight) of the tylosin compounds (i.e., tylosin A and tylosin A derivatives) in the composition consists of tylosin A. Other embodiments are contemplated wherein the tylosin A makes up less than 50% (by weight) of the tylosin compounds in the composition. To illustrate, in some such embodiments, the weight ratio of tylosin D to the total combined amounts of tylosin A and other tylosin A derivatives is at least about 1 : 1 , at least about 4: 1 , at least about 9:1, at least about 95:5, at least about 98:2, or at least about 99:1. In other such embodiments, about 100% (by weight) of the tylosin compounds in the composition consists of tylosin D.
[110] The methods discussed above for making 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide from tylosin A generally can be used (and, to the extent desirable, modified) for making 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide from tylosin B, C, and/or D in addition to (or instead of) tylosin A.
[Ill] Tylosin B, for example, has a hydroxyl instead of a mycarosyl substituent on the 5-mycanimosyl. Thus, a 20-piperidinyl intermediate derived from tylosin B does not require the first hydrolysis reaction discussed above in Section B-2. To the extent such an intermediate is exposed to the hydrolysis method discussed in Section B-2, the intermediate will generally remain non-reactive or begin hydro lyzing at the 23- mycinosyloxy substituent.
[112] Tylosin C has a hydroxyl rather than a methoxy at the 3-position of the 23- mycinosyloxy substituent. This difference generally has no effect with respect to the above-described methods. The sugar normally will cleave (i.e., hydro lyze) in the same manner and under the same conditions as the 23-mycinosyloxy of tylosin A during the hydrolysis described above in Section B-3.
[113] Tylosin D has a hydroxyl rather than a carbonyl at the 20-position. This hydroxyl is generally not transformed into a piperidinyl using the reductive amination method described above in Section B-I. Depending on the reaction conditions, however, it may become activated during the activation reaction described above in Section B-4, and then aminated with piperidine along with the 23 -position during the amination method described above in Section B-5.
C. Salts of Intermediates and Macrolides [114] This invention may be used to prepare macro lide compounds or intermediates both in the form of free compounds and in the form of salts. In addition, the reagents used in this invention may be in the form of salts. Salts may be, for example, acid addition salts. In general, an acid addition salt can be prepared using any inorganic or organic acid. Depending on the particular compound (and/or its crystalline structure), a salt of a compound may be advantageous due to one or more of the salt's chemical or physical properties, such as stability in differing temperatures and humidities, or a desirable solubility in water, oil, or other solvent. In some instances, a salt of a compound also may be used as an aid in the isolation or purification of a compound. In some embodiments (particularly where the salt is intended to be administered to an animal, as opposed to, for example, being used in an in vitro context), the salt is pharmaceutically acceptable.
[115] Salts can typically be formed by, for example, mixing the free macro lide or intermediate compound with an acid using various known methods in the art. Examples of often suitable inorganic acids include hydrochloric, hydrobromic, hydro iodic, nitric, carbonic, sulfuric, and phosphoric acid. Examples of often suitable organic acids include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of often suitable organic salts include cholate, sorbate, laurate, acetate, trifluoroacetate (or "CF3COOH" or "TFA"), formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartrate (and derivatives thereof, such as dibenzoyltartrate), citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate (and derivatives thereof), embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2- hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, β-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3- phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate. In some embodiments, the salt comprises a hydrochlorate, trifluoroacetate, mesylate, tosylate, tartrate, or citrate salt.
D . Preparation of Medicaments and Methods of Treatment Using Macrolides
[116] The macrolides prepared by the above-described processes may generally be used, for example, to treat pasteurellosis in animals, particularly livestock and poultry. In some embodiments, such a macrolide(s) is used to treat bovine animals having bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. In other embodiments, such a macro lide(s) is used to treat swine animals having swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Bordetella bronchiseptica.
[117] In general, a therapeutically-effective amount of one or more of such macro lides is administered to the recipient animal. As used in this patent, the term "therapeutically effective amount" constitutes an amount that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection. Generally, the therapeutically effective amount is defined as the amount necessary to achieve a concentration efficacious to control the target pathogen(s) at the site of infection (or, when used to prevent, reduce the risk of, or delay the onset of infection, at a site susceptible to infection). The concentration at the site of infection (or at a site susceptible to infection) is preferably at least equal to the MIC90 level (minimum inhibitory concentration, i.e., the concentration that inhibits the growth of 90% of the target pathogen) of the macrolide for the target pathogen. Such an amount may be administered to the animal recipient in two or more separate doses, although preferably is administered in a single dose. To the extent the macro lide(s) is administered with another active ingredient(s), the term "therapeutically effective amount" refers to the total amount of the macro lide(s) combined with the other active ingredient(s) that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection. [118] Factors affecting the preferred dosage regimen include the type {e.g., species and breed), age, weight, sex, diet, activity, and condition of the animal recipient; the severity of the pathological condition; the apparatus used to administer the composition, as well as the type of administration used; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular composition administered; the existence of an additional active ingredient(s) in the composition; and whether the composition is being administered as part of a drug and/or vaccine combination. Thus, the dosage actually employed can vary for specific animal patients, and, therefore, can deviate from the typical dosages set forth above. Determining such dosage adjustments is generally within the skill of those in the art using conventional means.
[119] In general, the macro lide(s) may be administered once to an animal, although it is contemplated that it may instead be administered multiple times.
[120] For cattle, the total amount of administered macrolide(s) is typically from about 0.1 to about 40 mg per kg body weight, and more typically from about 1 to about 10 mg per kg body weight. For example, in some embodiments, the amount administered to cattle is about 4 mg per kg body weight. Although the macro lide(s) may be given to cattle at any age, in some embodiments, the macro lide(s) is administered to cattle that are from about 1 months to about 1.5 years old, or from about 6 months to about 1 year old. In some embodiments, the macro lide(s) is administered to weaned calves entering the feedlots (often at about 6 months old). In still other embodiments, the cattle are calves at from about 2 to about 12 weeks old, and the macro lide(s) is administered for prophylaxis at a dosage of from about 1 to about 10 mg per kg of the body weight; or for treating an existing infection at a dosage of from about 2 to about 20 mg per kg of the body weight. [121] For swine, the total amount of administered macrolide(s) is typically from about 0.1 to about 50 mg per kg body weight, and more typically from about 1 to about 10 mg per kg body weight. For example, in some embodiments, the amount administered to swine is about 4 mg per kg body weight. In other embodiments, the amount administered to swine is about 5 mg per kg body weight. Although the macro lide(s) may be given to swine at any age, in some embodiments, the macro lide(s) is administered to grower- finisher pigs.
[122] The method of administration can be varied depending on animals, but in the case of large mammals such as cattle, swine, and horses, it is preferably administered orally or parenterally. "Parenteral administration" includes, for example, subcutaneous injections, intravenous injections, intramuscular injections, intrasternal injections, submucosal injections, and infusion. In some embodiments, for example, the animal recipient is a bovine animal, and the macro lide composition is administered subcutaneously, such as in the neck. In other embodiments, for example, the animal recipient is a swine animal, and the macrolide composition is administered intramuscularly.
[123] The macrolide(s) may be used to form a pharmaceutical composition (or "medicament"). It is contemplated that such a composition may entirely comprise one or more macro lides. Normally, however, the composition comprises other ingredients as well. [124] Other ingredients in the composition may comprise, for example, other active ingredients. Alternatively (or in addition), such other ingredients may comprise one or more pharmaceutically acceptable carriers, vehicles, and/or adjuvants (collectively referred to as "excipients"). The selection of such excipients will depend on various factors, such as the mode of administration; the apparatus used to administer the composition; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular composition; the existence of an additional active ingredient(s) in the composition; and whether the composition is being administered as part of a drug and/or vaccine combination. [125] Solid macrolide compositions may comprise, for example, saccharides such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose derivatives, such as carboxymethylcellulose sodium, ethylcellulose, and cellulose acetate; etc.
[126] Liquid macrolide compositions may comprise for example, water, isotonic physiological saline, Ringer's solution, ethyl alcohol, and/or phosphate buffer solution may be present. Such compositions also may comprise oils, such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil and/or polyhydric alcohols such as glycerol, propylene glycol, sorbitol, mannitol, polyethylene glycol, and poly(ethylene glycol-2-propylene glycol-2-poly ethylene glycol). It also, for example, may be desirable in some instances for the composition to comprise one or more preservatives. The presence of a preservative may, for example, provide a benefit for compositions or solvents that may be stored over lengthy periods of time, e.g., days, weeks, months, or years. When selecting a suitable preservative, factors to consider include, for example, its antimicrobial activity; the pH range at which it has the desired antimicrobial activity; the minimum concentration at which it has the desired antimicrobial activity; its aqueous solubility and other physical characteristics (e.g., potential to cause foaming); its suitability for parenteral use; its possible interactions with the active ingredient(s) (e.g. , its effect on the solubility of an active ingredient); its possible interactions with the non- active ingredients (e.g., its effect on the stability of the solvent); and any government regulations that may be applicable where the composition or solvent is being manufactured, sold, or used. Contemplated preservatives include, for example, parabens, propylene glycol, benzalkonium chloride, phenylethanol, chlorocresol, metacresol, ethanol, phenoxyethanol, and benzyl alcohol.
[127] Further discussion regarding pharmaceutically acceptable excipients that may be suitable for the macrolide composition may be found in, for example, "Gennaro, Remington: The Science and Practice of Pharmacy" (20th Edition, 2000) (incorporated by reference into this patent). To illustrate, other suitable excipients may include, for example, coloring agents; flavoring agents; and thickening agents, such as povidone carboxymethylcellulose, and/or hydroxypropyl methylcellulose. [128] Normally, the macro lide(s) occupies at least about 0.5% by weight of the pharmaceutical composition. For example, in some embodiments for swine use, suitable macro lide concentrations for parenteral administration may be, for example, from about 5 to about 500 mg/ml, from about 10 to about 100 mg/ml, or from about 20 to about 60 mg/ml (e.g., about 40 mg/ml). Exemplifying further, in some embodiments for bovine use, suitable macrolide concentrations for parenteral administration may be, for example, from about 5 mg/ml to about 2.0 g/ml, from about 10 mg/ml to about 1.0 g/ml, 50 to about 500 mg/ml, or from about 100 to about 300 mg/ml (e.g., 180 mg/ml).
[129] It should be recognized that the macrolide concentration can be varied depending on the dosage form. Where, for example, the macro lide(s) is administered parenterally, the macrolide concentration preferably is sufficient to provide the desired therapeutically effective amount of the macro lide(s) in a volume that is acceptable for parenteral administration. The maximum acceptable volume may vary, depending on, for example, the apparatus being used for the administration, type of parenteral administration, size of the recipient animal, and subjective desires of the user.
[130] Further discussion relating to the use of 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide and derivatives thereof to treat livestock and poultry disease may be found in, for example, U.S. Patent No. 6,514,946. As indicated earlier, that discussion is incorporated by reference into this patent. [131] This invention also is directed to kits that are, for example, suitable for use in performing the methods of treatment described above. The kit comprises a therapeutically effective amount of at least one of the above-described macro lides, and instructions for combining the macrolide(s) with at least one excipient, such as, for example, instructions for dissolving or suspending the macrolide(s) in a liquid excipient. The kit may further (or alternatively) comprise additional components, such as, for example, one or more apparatuses (e.g., a syringe) for administering a composition comprising (or derived from) the macrolide(s), one or more additional pharmaceutical or biological materials, one or more excipients, and/or one or more diagnostic tools. EXAMPLES
[132] The following examples are merely illustrative of embodiments of the invention, and not limiting to the remainder of this disclosure in any way.
[133] Example 1. Preparation of 20,23-dipiperidinyl-5-O-mycaminosyl- tylonolide from tylosin A.
Figure imgf000053_0001
[134] Part A. Reductive amination. Preparation of 23-O-Mycinosyl-20- Piperidinyl-5-O-Mycaminosyl-Tylonolide Compound (2).
Figure imgf000053_0002
(D (2)
Toluene (19.2 kg), tylosin A (1) (3.68 kg; >80% tylosin A; >95% tylosin A, B, C, & D), piperidine (0.40 kg), and formic acid (0.55 kg) were charged to a reactor. The mixture was heated to 70-800C, while being stirred. Stirring was then continued at that temperature for 1-2 more hours. The formation of the 20-piperidinyl-tylosin compound (2) was monitored by HPLC. After reaction completion (< 2% tylosin A (I)), the product mixture was cooled to ambient temperature.
[135] Part B. Acid hydrolysis of mycarosyloxy substituent. Preparation of 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound (3).
Figure imgf000054_0001
(2) (3)
HBr (48% HBr diluted to 24%) was added to the product mixture of Part A while stirring and maintaining the mixture at less than 4O0C. Afterward, the phases in the product mixture were separated using a 20-minute phase separation period. The product mixture was at 20-250C during this phase separation. HPLC of the lower phase was used to confirm reaction completion (< 2% 20-piperidinyl-tylosin compound (2)).
[136] Part C. Acid hydrolysis of mycinosyloxy substituent. Preparation of 23-Hydroxyl-20-Piperidinyl-5-O-Mycaminosyl-Tylonolide (4).
Figure imgf000054_0002
(3) (4)
Twenty- four percent HBr (18.4 L) was added at ambient temperature to the aqueous phase obtained from Part B, followed by heating to 54 ± 30C within about 1 hour while stirring. Stirring was continued at this temperature for 2-4 more hours, while the reaction was monitored using HPLC. After completion of the reaction (< 2% 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound (3)), the mixture was cooled to ambient temperature using a -1O0C cooling jacket. After cooling, the mixture was extracted with dichloro methane three times (9.8 kg each time). The aqueous product was cooled to 4-80C, and then 6 N NaOH (33.6 kg) was slowly added to adjust the pH to >10. The resulting mixture was extracted with dichloromethane three times (with 32.6 kg, 29.3 kg, and 24.5 kg) at ambient temperature. The combined organic phases were charged to a separate reactor. Sodium sulfate (2.9 kg; Na2SO4) was added and filtered off. Dichloromethane (4.9 kg) was then added and removed via distillation. The resulting crude product was dissolved and re-crystallized twice in tert-butyl methyl ether (6.1 kg each time) at ambient temperature. Afterward, the product was isolated on a Nutsch filter, washed twice with tert-butyi methyl ether (1.0 kg each time), and dried in a tray dryer under vacuum overnight at 4O0C. The final product was analyzed using HPLC. [137] Part D. Iodination. Preparation of activated compound (5).
Figure imgf000055_0001
Triphenylphosphine (0.9 kg) and pyridine (0.3 kg; free of water) were dissolved into dichloromethane (11.7 kg) at ambient temperature. Iodine (0.8 kg) was then added. The resulting mixture was then stirred until all the iodine dissolved. The mixture was then cooled to 130C. The cooled mixture was added to the product from Part C in dichloromethane (11.7 kg) while stirring at 15 ± 30C. The reaction was monitored by HPLC, and was determined to be completed in 2-2.5 hours (< 2% 23-hydroxyl-20- piperidinyl-5 -0-mycamino syl-tylono lide compound) .
[138] Part E. Animation. Preparation of 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide (6).
Figure imgf000055_0002
Potassium carbonate (1.8 kg), acetonitrile (16.7 kg), and piperidine (1.1 kg) were added to the product of Part D. The resulting mixture was then heated to 780C while distilling off dichloromethane. After solvent exchange to acetonitrile, the mixture was stirred at 2-2.5 hours at reflux, and then cooled to ambient temperature. Afterward, the residual potassium carbonate was filtered off, the filter cake was washed with acetonitrile (2.8 kg), and the solvent was distilled off under vacuum at a 5O0C jacket temperature. The resulting residue was dissolved in ethyl acetate (15.8 kg), and mixed with 0.5 N HCl (35.6 kg). The phases were separated at ambient temperature, and the lower aqueous phase was extracted three times with ethyl acetate (15.8 kg were used each time). The resulting aqueous phase was set to a pH of 11 by addition of 6 N NaOH (6.4 kg) and extracted three times with dichloromethane (18.7 kg each time) at ambient temperature. The combined lower organic phases were recharged to the reactor with sodium sulfate (5.3 kg). The mixture was then filtered to form a cake, which, in turn, was washed with dichloromethane (4.9 kg) and dried under vacuum at a jacket temperature of 5O0C to form a macro lide product. This product, in turn, was mixed with acetonitrile (21.7 L) and re-crystallized. The resulting crystals were isolated on a Nutsch filter, washed twice with cold acetonitrile (3.5 L each time), and dried under vacuum at 4O0C overnight to form macro lide (5) product. The composition of the product was confirmed using HPLC.
[139] Example 2. Alternative Amination. Preparation of 20,23- Dipiperidinyl-5-O-Mycaminosyl-Tylonolide (2).
Figure imgf000056_0001
Potassium carbonate (0.94 kg), xylene (5 L), and piperidine (0.55 kg) are added to 1.0 kg of activated compound (1) made in accordance with the procedure in Part D. The resulting mixture is then heated to 95-1050C for 15 hours. Work-up includes dissolving the K2CO3 in water; removing excess piperidine; extracting into diluted HCl; extracting into tert-butyi methyl ether at a pH of 11; conducting a solvent switch to ethanol; and precipitating, isolating, and drying of the crude product. The product is then re- crystallized from methyl acetate or ethyl acetate. The composition of the product is confirmed using HPLC. [140] Example 3. Another illustrative preparation of 20,23-dipiperidinyl-5- O-mycaminosyl-tylonolide.
[141] Part A. Reductive animation. Preparation of 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound (2).
Figure imgf000057_0001
(D (2)
Tylosin phosphate (1) and dichloromethane (1.3 L per kg tylosin phosphate) were charged to a reactor. The resulting mixture was stirred to produce a clear solution. Next, piperidine (1.2 eq, based on the tylosin phosphate), formic acid (4.5 eq, based on the tylosin phosphate), and toluene (6.7 L per kg tylosin phosphate) were sequentially charged to the reactor. The resulting mixture was heated to 760C while being stirred. Stirring was then continued at that temperature for 2.5 hours. Additional piperidine (0.1 eq, based on the tylosin phosphate) was then charged, and the resulting mixture was stirred at 760C for an additional hour. The product mixture was cooled to 5O0C.
[142] Part B. Acid hydrolysis of mycarosyloxy substituent. Preparation of 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide (4).
Figure imgf000057_0002
(2) (4)
[143] Aqueous HBr (23.3 eq, based on the tylosin phosphate used in Part A) was added to the product mixture of Part A at 5O0C. The resulting mixture was stirred at 560C for 5 hours. HPLC was used to monitor the reaction. [144] Once the desired conversion was obtained, the product mixture was cooled.
The aqueous phase was extracted twice with dichloromethane at 25-3O0C. The aqueous phase was then cooled to O0C, and the pH was adjusted to 10-10.5 with NaOH at <5°C. Afterward, the aqueous phase was extracted twice with dichloromethane at 2O0C. The resulting combined organic phases were extracted twice with aqueous NaHCO3. The dichloromethane was then removed from the combined organic phases via distillation, and replaced with isopropyl alcohol. Afterward, heptane at 450C was added to initiate precipitation. The mixture was then stirred at O0C. Afterward, the crystalline product was isolated by filtration. The isolated crystals were washed with heptane and isopropyl alcohol, dried, and analyzed using HPLC.
[145] The above procedure made 0.23 kg of product per kilogram of tylosin phosphate used in Part A. This product may contain isopropyl alcohol. To remove the isopropyl alcohol, the product may be dissolved in toluene and dichloro methane, followed by distillation.
[146] Part C. Iodination. Preparation of activated compound (5).
Figure imgf000058_0001
[147] Triphenylphosphine (0.41 kg per kg of product of Part B) was dissolved in dichloromethane (12 L per kg of triphenylphosphine, <100 ppm H2O) at 250C. Pyridine (0.3 kg per kg triphenylphosphine) was then added. Next, iodine (0.9 kg per kg of triphenylphosphine) was added in 5 portions at 250C. The resulting mixture was stirred for 40 minutes at 250C, and then cooled to -60C. The mixture was then added to the product from Part B over 50 minutes while stirring at -60C. Afterward, stirring was continued for 7 hours while maintaining the mixture at -50C. The reaction was monitored by HPLC (if sufficient conversion is not reached, the mixture may be stirred at -50C for an additional amount of time, e.g., 1.5 hours). [148] When the desired conversion was reached, the product mixture was washed with aqueous Na2SO3 solution at -50C. Dichloromethane was then removed from the organic phase by distillation, and replaced with tetrahydrofuran. [149] Part D. Amination. Preparation of 20,23-dipiperidinyl-5-O- mycaminosyl-tylonolide (6).
Figure imgf000059_0001
[150] Piperidine (0.55 kg per kg of product from Part B) was added to the product from Part C, followed by potassium carbonate (0.94 kg per kg of product from Part B). The resulting mixture was heated to 550C, and then maintained at that temperature for 3 hours while stirring. Afterward, the mixture was heated to 720C over 1 hour, and then stirred at that temperature for 6 hours. The composition of the product was analyzed using HPLC.
[151] The words "comprise," "comprises," and "comprising" in this patent (including the claims) are to be interpreted inclusively rather than exclusively. This interpretation is intended to be the same as the interpretation that these words are given under United States patent law.
[152] The term "pharmaceutically acceptable" is used adjectivally in this patent to mean that the modified noun is appropriate for use in a pharmaceutical product. When it is used, for example, to describe an excipient or a salt, it characterizes the excipient or salt as having a benefϊt(s) that outweighs any deleterious effect(s) that the excipient or salt may have to the intended recipient animal.
[153] Unless otherwise characterized by this patent, the term "ambient temperature" means a temperature of from about 20 to about 250C.
[154] All references cited in this patent are incorporated by reference into this patent. [155] The above detailed description of preferred embodiments is intended only to acquaint others skilled in the art with the invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This invention, therefore, is not limited to the above embodiments, and may be variously modified.

Claims

WE CLAIM:
1. A process for making a macrolide or a salt thereof, wherein: the macrolide corresponds in structure to Formula (I):
Figure imgf000061_0001
the process comprises: reacting tylosin A (or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent to form a 20-piperidinyl-tylosin compound, reacting a 20-piperidinyl-tylosin compound with an acid to form a 23 -0-mycino syl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound, reacting a 23 -O-mycinosyl-20-piperidinyl-5 -0-mycamino syl- tylono lide compound with an acid to form a 23-hydroxyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound, activating a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound with an activating agent to form an activated compound, or reacting an activated compound with a piperidinyl compound of Formula (VII); the piperidinyl compound of Formula (II) corresponds in structure to:
Figure imgf000061_0002
the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III):
Figure imgf000062_0001
the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound corresponds in structure to Formula (IV):
Figure imgf000062_0002
the 23 -hydroxyl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound corresponds in structure to Formula (V):
Figure imgf000062_0003
the activated compound corresponds in structure to Formula (VI):
Figure imgf000063_0001
the piperidinyl compound of Formula (VII) corresponds in structure to:
Figure imgf000063_0002
L is a leaving group; as to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen; and as to R4, R5, and R6:
R4 and R6 are each methyl, and R5 is hydrogen, R4 and R6 are each hydrogen, and R5 is methyl, or R4, R5, and R6 are each hydrogen.
2. A process of claim 1, wherein the process comprises reacting tylosin A (or a salt thereof), the piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent to form the 20-piperidinyl-tylosin compound.
3. A process of claim 1, wherein the process comprises reacting the 20- piperidinyl-tylosin compound with an acid to form the 23-O-mycinosyl-20-piperidinyl-5- O-mycaminosyl-tylonolide compound.
4. A process of claim 1, wherein the process comprises reacting the 23-0- mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound with an acid to form the 23 -hydroxyl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound.
5. A process of claim 4, wherein the process further comprises preparing the 23- O-mycinosyl^O-piperidinyl-S-O-mycaminosyl-tylonolide-compound by a process comprising reacting the 20-piperidinyl-tylosin compound with an acid.
6. A process of claim 5, wherein at least a portion of the 23-O-mycinosyl-20- piperidinyl-5-O-mycaminosyl-tylonolide compound and at least a portion of the 20- piperidinyl-tylosin compound are reacted with HBr.
7. A process of claim 1, wherein the process comprises activating the 23- hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound with an activating agent to form the activated compound.
8. A process of claim 1, wherein the process comprises reacting the activated compound with the piperidinyl compound of Formula (VII).
9. A process of claim 8, wherein: the process further comprises: reacting tylosin A (or a salt thereof), piperidine, and formic acid in the presence of toluene; reacting the 20-piperidinyl-tylosin compound with HBr; reacting the 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound with HBr; and activating the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound with an activating agent; the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III-A):
Figure imgf000064_0001
(HI-A); the IS-O-mycinosyl-lO-piperidinyl-S-O-mycaminosyl-tylonolide compound corresponds in structure to Formula (IV-A):
Figure imgf000065_0001
(IV-A); the 23 -hydroxyl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound corresponds in structure to Formula (V-A):
Figure imgf000065_0002
the activated compound corresponds in structure to Formula (VI-A):
Figure imgf000065_0003
the activating agent is prepared by a process comprising mixing I2, triphenylphosphine, and pyridine; the piperidinyl compound of Formula (VII) comprises piperidine; and the macro lide corresponds in structure to Formula (I -A):
Figure imgf000066_0001
(I-A).
10. A method for treating a disease, wherein the disease is selected from the group consisting of pasteurellosis, swine respiratory disease, and bovine respiratory disease; and the method comprises: preparing a macro lide or pharmaceutically acceptable salt thereof in accordance with any one of claims 1, 2, 3, 4, 5, 6, 7, 8, and 9; and administering a therapeutically effective amount of the macro lide or salt to an animal in need of such treatment.
11. A process for making a 20-piperidinyl-tylosin compound or a salt thereof, wherein: the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III):
Figure imgf000066_0002
the process comprises reacting tylosin A (or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent; the piperidinyl compound of Formula (II) corresponds in structure to:
Figure imgf000067_0001
as to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen.
12. A process for making a 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound or a salt thereof, wherein: the 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound corresponds in structure to Formula (IV):
Figure imgf000067_0002
the process comprises reacting a 20-piperidinyl-tylosin compound with HBr; the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III):
Figure imgf000067_0003
as to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen.
13. A process for making a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound or a salt thereof, wherein: the 23 -hydroxyl-20-piperidinyl-5 -0-mycamino syl-tylono lide compound corresponds in structure to Formula (V):
Figure imgf000068_0001
the process comprises reacting a 23-O-mycinosyl-20-piperidinyl-5-O- mycaminosyl-tylonolide compound with an acid; the 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound corresponds in structure to Formula (IV):
Figure imgf000068_0002
as to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen.
14. A process for making an activated compound or a salt thereof, wherein: the activated compound corresponds in structure to Formula (VI):
Figure imgf000069_0001
the process comprises activating a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl- tylonolide compound with an activating agent; the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide corresponds in structure to Formula (V):
Figure imgf000069_0002
L is a leaving group; and as to R1, R2, and R3:
R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen.
15. A process of claims 1, 2, and 11, wherein the non-polar solvent comprises toluene.
16. A process of claims 1, 7, 8, and 14, wherein L is iodo.
17. A process of any one of claims 1,2,3,4,5,6,7,8, 11, 12, 13, 14, and 15, wherein R1, R2, and R3 are each hydrogen.
18. A process of any one of claims 1, 2, 3, 4, 5, 6, 7, and 8, wherein R4, R5, and R6 are each hydrogen.
19. A process of any one of claims 1, 2, 3, 4, 5, 6, 7, and 8, wherein R1, R2, R3, R4, R5, and R6 are each hydrogen.
PCT/EP2007/057710 2006-07-28 2007-07-26 Macrolide synthesis process WO2008012343A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
KR1020147011035A KR101538599B1 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
CA2657483A CA2657483C (en) 2006-07-28 2007-07-26 Macrolide synthesis process
KR1020097003914A KR101456308B1 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
MX2009001072A MX2009001072A (en) 2006-07-28 2007-07-26 Macrolide synthesis process.
BRPI0715642A BRPI0715642C8 (en) 2006-07-28 2007-07-26 processes to produce a macrolide or a salt thereof, and to produce a compound
EP07787934A EP2089408B1 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
PL07787934T PL2089408T3 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
AT07787934T ATE528312T1 (en) 2006-07-28 2007-07-26 METHOD FOR SYNTHESIS OF MACROLIDS
CN200780031395XA CN101506220B (en) 2006-07-28 2007-07-26 Macrolide synthesis process
SI200730813T SI2089408T1 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
NZ574193A NZ574193A (en) 2006-07-28 2007-07-26 Macrolide synthesis process
JP2009521274A JP5323696B2 (en) 2006-07-28 2007-07-26 Macrolide synthesis method
ES07787934T ES2374950T3 (en) 2006-07-28 2007-07-26 MACROLIDOS SYNTHESIS PROCEDURE.
AU2007278195A AU2007278195B2 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
UAA200901136A UA98303C2 (en) 2006-07-28 2007-07-26 Macrolide synthesis process
ZA2009/00387A ZA200900387B (en) 2006-07-28 2009-01-16 Macrolide synthesis process
HK10100071.0A HK1132510A1 (en) 2006-07-28 2010-01-06 Macrolide synthesis process

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83406706P 2006-07-28 2006-07-28
US60/834,067 2006-07-28
EP06118159.0 2006-07-31
EP06118159 2006-07-31

Publications (2)

Publication Number Publication Date
WO2008012343A2 true WO2008012343A2 (en) 2008-01-31
WO2008012343A3 WO2008012343A3 (en) 2008-04-17

Family

ID=38694928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/057710 WO2008012343A2 (en) 2006-07-28 2007-07-26 Macrolide synthesis process

Country Status (12)

Country Link
US (4) US8227429B2 (en)
EP (1) EP2089408B1 (en)
JP (2) JP5323696B2 (en)
KR (2) KR101456308B1 (en)
AU (1) AU2007278195B2 (en)
CA (1) CA2657483C (en)
CO (1) CO6160240A2 (en)
HK (1) HK1132510A1 (en)
MX (1) MX2009001072A (en)
PL (1) PL2089408T3 (en)
WO (1) WO2008012343A2 (en)
ZA (1) ZA200900387B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019112A1 (en) * 2007-07-26 2009-01-28 Intervet International BV Macrolide solid-state forms
WO2014187957A1 (en) * 2013-05-23 2014-11-27 Bayer Animal Health Gmbh Tylosin derivatives and method for preparation thereof
US9593140B2 (en) 2011-11-25 2017-03-14 Bayer Intellectual Property Gmbh Antibacterial tylosin derivatives and methods for their preparation
WO2022117701A1 (en) 2020-12-03 2022-06-09 Intervet International B.V. A method of treating foot rot

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4919124B2 (en) 2010-03-31 2012-04-18 ブラザー工業株式会社 cartridge
JP5115607B2 (en) 2010-08-31 2013-01-09 ブラザー工業株式会社 Caps and cartridges
JP5884436B2 (en) 2011-11-24 2016-03-15 ブラザー工業株式会社 cartridge
JP6102573B2 (en) 2013-06-28 2017-03-29 ブラザー工業株式会社 cartridge
JP6127779B2 (en) 2013-06-28 2017-05-17 ブラザー工業株式会社 cartridge
JP6060866B2 (en) 2013-09-20 2017-01-18 ブラザー工業株式会社 Image forming apparatus
JP6064867B2 (en) 2013-10-31 2017-01-25 ブラザー工業株式会社 cartridge
JP6136938B2 (en) 2014-01-06 2017-05-31 ブラザー工業株式会社 Developer cartridge
JP6079688B2 (en) 2014-03-31 2017-02-15 ブラザー工業株式会社 cartridge
JP6137028B2 (en) 2014-03-31 2017-05-31 ブラザー工業株式会社 cartridge
JP6079687B2 (en) 2014-03-31 2017-02-15 ブラザー工業株式会社 cartridge
JP6221905B2 (en) 2014-03-31 2017-11-01 ブラザー工業株式会社 cartridge
JP6137027B2 (en) 2014-03-31 2017-05-31 ブラザー工業株式会社 cartridge
JP6135583B2 (en) 2014-03-31 2017-05-31 ブラザー工業株式会社 cartridge
JP6137029B2 (en) 2014-03-31 2017-05-31 ブラザー工業株式会社 cartridge
CN105202299B (en) * 2015-08-08 2017-04-12 周朝辉 Auto-fill two-layer in-half wear resistant elbow of concrete pump truck and manufacturing method of wear resistant elbow
CN111349130A (en) * 2018-12-21 2020-06-30 齐鲁动物保健品有限公司 Tildipirosin crystal form B and preparation method thereof
KR102494244B1 (en) 2020-12-02 2023-02-01 호서대학교 산학협력단 Composition for skin regeneration and wound treatment comprising an absolute type essential oil derived from a Smilax china Flower as an active ingredient

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE667952A (en) * 1964-08-05
GB1587685A (en) 1977-03-09 1981-04-08 Microbial Chem Res Found Macrolactone derivatives and their production
US4203976A (en) * 1978-08-02 1980-05-20 Merck & Co., Inc. Sugar derivatives of C-076 compounds
US4438109A (en) 1980-07-25 1984-03-20 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Tylosin derivatives
AU551142B2 (en) 1981-07-09 1986-04-17 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Tylosin derivatives
US4454314A (en) 1982-08-02 1984-06-12 Pfizer Inc. Antibacterial mycaminosyl tylonolide and related macrolide derivatives
IL69666A (en) 1982-09-13 1987-10-20 Lilly Co Eli 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
IL71032A0 (en) 1983-02-28 1984-05-31 Lilly Co Eli C-20 and c-23-modified macrolide derivatives
US4468511A (en) 1983-02-28 1984-08-28 Eli Lilly And Company C-20- And C-23-Modified macrolide derivatives
US4629786A (en) * 1983-02-28 1986-12-16 Eli Lilly And Company C-20- and C-23 modified macrolide derivatives
ZA841277B (en) 1983-02-28 1985-09-25 Lilly Co Eli C-20-and c-23-modified macrolide derivatives
DE3444006A1 (en) 1983-11-30 1985-06-05 Toyo Jozo K.K., Tagata, Shizuoka 14-DE (HYDROXYMETHYL) -MYCAMINOSYLTYLONOLIDE DERIVATIVES
GB2171991B (en) 1985-03-06 1988-08-17 Satoshi Omura Novel macrolide derivatives, process for preparing same, and antibacterial compositions thereof
US4921947A (en) 1986-03-31 1990-05-01 Eli Lilly And Company Process for preparing macrolide derivatives
US4920103A (en) 1986-09-29 1990-04-24 Eli Lilly And Company Modifications of mycinose and 3-O-demethylmycinose in tylosin-type macrolides
US4820694A (en) 1986-09-29 1989-04-11 Eli Lilly And Company Modifications of 3-O-demethylmycinose in macrocin and lactenocin
YU45033B (en) 1987-04-14 1991-06-30 Pliva Zagreb Process for preparing 10,11,12,13-tetrahydro derivative
US5026832A (en) 1988-12-26 1991-06-25 Toyo Jozo Co., Ltd. 9-dihydro-9-O-alkyldesmycosin derivatives
US5140014A (en) 1989-11-13 1992-08-18 Abbott Laboratories Rosaramicin derivatives and method of treating bacterial infections
JP3264926B2 (en) 1992-01-14 2002-03-11 財団法人微生物化学研究会 3,4'-dideoxymycaminosyltylonolide derivative and method for producing the same
TW226373B (en) 1992-07-15 1994-07-11 Pfizer
US5677287A (en) 1993-03-18 1997-10-14 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at C-20
JPH08508038A (en) 1993-07-15 1996-08-27 ファイザー・インク． Amide derivatives of 16-membered macrolide antibiotics
WO1996009312A1 (en) 1994-09-22 1996-03-28 Pfizer Inc. Antibiotic macrolides
EP0778283A3 (en) * 1995-12-05 1998-01-28 Pfizer Inc. Antibiotic macrolides
CO5080775A1 (en) 1998-03-02 2001-09-25 Lilly Co Eli TREATMENT OF VIRAL DISEASE IN PIGS
AU763732B2 (en) 1999-08-30 2003-07-31 Zaidan Hojin Biseibutsu Kagaku Kenkyukai Macrolide antibiotics and treatment of pasteurellosis
EP1103181A1 (en) 1999-11-25 2001-05-30 Novartis AG Combination of N-phenyl-N'-benzoyl urea derivatives and avermectine compounds for parasite control
US6462026B1 (en) 2001-02-16 2002-10-08 Enanta Pharmaceuticals, Inc. Bicyclic leucomycins
US6506885B1 (en) * 2001-09-27 2003-01-14 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
US6576615B2 (en) 2001-11-08 2003-06-10 Enanta Pharmaceuticals, Inc. 4′-O-substituted tylosin analogs
US6664240B2 (en) 2001-11-15 2003-12-16 Enanta Pharmaceuticals, Inc. Tylosin derivatives having antibacterial activity
US6710034B2 (en) 2002-04-19 2004-03-23 Enanta Pharmaceuticals, Inc. 5-O-mycaminosyltylonide derivatives
US6753415B2 (en) 2002-04-19 2004-06-22 Enanta Pharmaceuticals, Inc. 23-O-substituted 5-O-mycaminosyltylonide derivatives
EP2019112A1 (en) 2007-07-26 2009-01-28 Intervet International BV Macrolide solid-state forms
SI2109614T1 (en) 2007-02-01 2014-12-31 Intervet International B.V. Enantioselective synthesis of 6-amino-7-hydroxy-4, 5, 6, 7-tetrahydro-imidazo š4, 5, 1-jkćš1ć-benzazepin-2 š1hć-one and zilpaterol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019112A1 (en) * 2007-07-26 2009-01-28 Intervet International BV Macrolide solid-state forms
WO2009013351A2 (en) * 2007-07-26 2009-01-29 Intervet International B.V. Macrolide solid-state forms
WO2009013351A3 (en) * 2007-07-26 2009-04-02 Intervet Int Bv Macrolide solid-state forms
KR20100044864A (en) * 2007-07-26 2010-04-30 인터벳 인터내셔널 비.브이. Macrolide solid-state forms
EP3170833A1 (en) * 2007-07-26 2017-05-24 Intervet International B.V. 20,23-piperidinyl-5-o-mycaminosyl-tylonolide polymorphs
KR102508115B1 (en) 2007-07-26 2023-03-08 인터벳 인터내셔널 비.브이. Macrolide solid-state forms
US9593140B2 (en) 2011-11-25 2017-03-14 Bayer Intellectual Property Gmbh Antibacterial tylosin derivatives and methods for their preparation
WO2014187957A1 (en) * 2013-05-23 2014-11-27 Bayer Animal Health Gmbh Tylosin derivatives and method for preparation thereof
US9771389B2 (en) 2013-05-23 2017-09-26 The Kitasako Institute Tylosin derivatives and method for preparation thereof
RU2714482C2 (en) * 2013-05-23 2020-02-18 Байер Энимэл Хельс ГмбХ Tylosin derivatives and method for production thereof
WO2022117701A1 (en) 2020-12-03 2022-06-09 Intervet International B.V. A method of treating foot rot

Also Published As

Publication number Publication date
US8518900B2 (en) 2013-08-27
KR20090040903A (en) 2009-04-27
US20090042815A1 (en) 2009-02-12
ZA200900387B (en) 2009-12-30
WO2008012343A3 (en) 2008-04-17
US20120122808A1 (en) 2012-05-17
EP2089408B1 (en) 2011-10-12
PL2089408T3 (en) 2012-03-30
AU2007278195A1 (en) 2008-01-31
JP5323696B2 (en) 2013-10-23
HK1132510A1 (en) 2010-02-26
CA2657483A1 (en) 2008-01-31
CA2657483C (en) 2012-10-09
KR101538599B1 (en) 2015-07-21
MX2009001072A (en) 2009-06-26
KR20140072126A (en) 2014-06-12
US20110053875A1 (en) 2011-03-03
JP5827975B2 (en) 2015-12-02
KR101456308B1 (en) 2014-11-03
US8263753B2 (en) 2012-09-11
US20120208779A1 (en) 2012-08-16
CO6160240A2 (en) 2010-05-20
JP2009544666A (en) 2009-12-17
US8461121B2 (en) 2013-06-11
JP2014012668A (en) 2014-01-23
US8227429B2 (en) 2012-07-24
AU2007278195B2 (en) 2012-09-13
EP2089408A2 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
EP2089408B1 (en) Macrolide synthesis process
JP4102440B2 (en) Novel erythromycin derivatives, methods for their preparation and their use as pharmaceuticals
CN101506220B (en) Macrolide synthesis process
EP0349100B1 (en) Macrolide compositions for treating gastro-intestinal motility disorders
JP4083824B2 (en) Novel erythromycin derivatives, their production and use as pharmaceuticals
JPH11315093A (en) 3,6-ketal and enol ether macrolide antibiotic
DK158357B (en) 9-DEOXO-9A- (ETHYL OR N-PROPYL) -9A-AZA-9A-HOMOERYTHROMYCIN A AND PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
NZ574193A (en) Macrolide synthesis process
EP0316128B1 (en) Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin a derivatives
EP1627883A1 (en) 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A derivatives
JPS5827799B2 (en) 4″-amino-oleandomycin derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780031395.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07787934

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657483

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 574193

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007278195

Country of ref document: AU

Ref document number: 2007787934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009521274

Country of ref document: JP

Ref document number: MX/A/2009/001072

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 09007875

Country of ref document: CO

Ref document number: 516/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007278195

Country of ref document: AU

Date of ref document: 20070726

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097003914

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: A200901136

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2009107167

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0715642

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090127